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ABSTRACT 
 
Despite tremendous efforts that have been made to develop new therapeutic strategies, 
including the fabrication of novel bioactive scaffolds, the application of various 
growth factors and gene-modified cells in pre-clinical or clinical settings, bone defect 
healing still poses a great challenge to orthopaedic surgeons. 
 
Increasing evidence supports that cell-based therapy has emerged as one of the most 
promising therapeutic approaches for tissue repair and regeneration due to the 
inherent characteristics of mesenchymal stromal cells (MSCs) in respect to their self-
renewal capacity and multipotent differentiation potential. More interestingly, recent 
experimental evidence suggests that implanted MSCs have a close communication 
with host cells, and the contribution of donor cells is beyond their direct conversion 
into bone forming cells. Collectively, these findings indicate that transplanted donor 
cells play an important role in bone defect healing. However, how transplanted donor 
cells initiate osteogenesis, their role in the recruitment of host MSCs to form 
functional structures and the mechanisms behind these processes remain largely 
undefined. Motivated by the issues mentioned above, the purpose of this thesis was to 
unveil the interactions between donor cells and host cells during osteogenesis and in 
particular the involvement of VEGF, the CXCL12/CXCR4 axis and the PI3K/Akt 
signaling pathway in cell recruitment and donor-host cell interactions. This project 
was designed as three separate but closely-linked segments which, in the end, led to 
three independent papers.  
 
The first segment of this project investigated how osteogenically differentiated human 
mesenchymal stromal cells (O-hMSCs) were involved in the osteogenic processes and 
how they interacted with the host cells after implantation. Histology, 
immunohistochemistry and in situ hybridisation were some of the techniques applied 
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in this part of the study to identify the interaction between donor cells and host cells in 
vivo. Results revealed that in both ectopic (subcutaneous pocket) and orthotopic (skull 
defect) sites of severe combined immunodeficiency (SCID) mice, donor O-hMSCs 
could recruit host cells to initiate osteogenesis. We demonstrated that the ratio of 
donor cells and host cells inside the implants was significantly dependent on the local 
micro-environment and directly correlated with osteogenesis. The findings from this 
study provided clear evidence that donor O-hMSCs play an integral role in host cell 
recruitment during osteogenesis.  
 
Osteogenesis and angiogenesis are two closely correlated processes during functional 
bone formation and regeneration. As the best characterised angiogenic mediator, 
VEGF is believed to play a crucial role in skeletal development by enhancement of 
the coupling of angiogenesis and osteogenesis. The second segment of this project 
was designed to investigate the role of VEGF in the interaction between 
undifferentiated and osteogenically differentiated bone marrow stromal cells (MSCs 
and OMSCs) in vitro and in vivo. VEGF secretion increased dramatically in MSCs 
after osteogenic differentiation. Furthermore, the secretion of VEGF from OMSCs 
altered the expression pattern of CXCL12/CXCR4 in MSCs in vitro, which may be 
responsible for the increased cell migration in vivo. In situ hybridisation demonstrated 
that donor OMSCs recruited host cells during the osteogenic processes at the 
orthotopic sites, and blocking VEGF with neutralizing antibody resulted in a 
significant decrease of host cell recruitment and new bone formation. These findings 
suggest that the interaction between donor OMSCs and host MSCs might be mediated 
by the paracrine effect of VEGF and the activation of CXCL12/CXCR4 axis, 
resulting in enhanced host MSCs migration to the implantation site. 
 
Based on the findings of the second segment, subsequent experiments were designed 
to determine the possible mechanisms that drive the host cells to migrate to the defect 
site. Our co-culture studies demonstrated that OMSCs induced phenotypic changes in 
MSCs via dimerization of platelet-derived growth factor receptor (PDGFR), which 
then activated the signal transduction. The PI3K/Akt signaling pathway was probed 
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by using targeted PI3K inhibitor LY294002, and the activity was monitored by 
Western blotting analysis using total- and phospho-Akt specific antibodies. 
Downstream targets of the PI3K/Akt signaling pathway, mTOR, p70
S6k
 and PAK1, 
which regulate actin organization and cell motility, were also activated in the presence 
of OMSCs-derived conditioned medium. The findings from this segment 
demonstrated that VEGF secreted by OMSCs plays a critical role in recruiting host 
cells to accelerate osteogenesis via the activation of PDGFRs, which then activate the 
PI3K/Akt signaling pathway. 
 
In summary, the body of work presented in this dissertation has demonstrated that the 
interactions between donor cells and host cells were critical for the initiation of 
ectopic and orthotopic osteogenesis and that this process was mediated by the VEGF, 
CXCL12/CXCR4 and the PI3K/Akt signaling pathway. The findings from this 
dissertation may provide a scientific rationale for the development of novel 
therapeutic strategies in the treatment and management of bone defects. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Preface 
Orthopaedic surgeons have long held the aspiration to heal bone defects resulting 
from traumatic insult, oncological resection, congenital deformities, and progressive 
degenerative diseases. To realize this ambition, innumerable studies have been 
conducted to advance autogeneic, allogeneic and even xenogeneic bone graft 
therapies [1-3]. Although some favourable results have been achieved in animal 
studies or clinical trials [4-6], the outcomes are far from satisfactory due to limited 
availability, donor site morbidity, insufficient integration and immunological 
repulsive reactions in the recipient against allo- or xenogeneic bone grafts [7]. 
Advances in materials science, cell and molecular biology, especially in the 
knowledge of the underlying mechanisms of bone healing have thrown a new light on 
the repair and regeneration of bone defects [8].  
 
Cell-based therapy for bone regeneration offers a paradigm shift that may provide 
alternative solutions from the traditional invasive surgeries. Significant efforts have 
been devoted to characterizing the potential cell sources that are relatively abundant 
and easily accessible. However, there has not been a universal understanding as to 
which expansion conditions are optimal for the manufacture of MSCs intended for 
bone repair and regeneration. For example, different cell seeding density [9-11], 
vascular endothelial growth factor (VEGF) application [12-15] and low oxygen 
tension [16-18] have all been reported to improve the longevity and the osteogenic 
potency of MSCs. The induction of MSCs towards osteoblast-like cells prior to the 
implantation is also found to favour more bone regeneration [19-21]. In previous 
studies the concept of cell-based bone tissue engineering has been tested using 
collagen type I matrices seeded with cells of osteogenic potential and implanted into 
sites with osseous damage [22, 23]. New bone formation was found in defect sites 
implanted with bone marrow derived-osteoblasts (OBs) at 4 weeks, while no obvious 
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new bone formation was identified at the same time point without OBs transplantation 
[23]. Therefore, focus has been directed on elucidating the intrinsic controls that keep 
the transplanted donor cells alive and direct them along particular differentiation 
pathways, which may interact with the microenvironment where the host 
mesenchymal stromal cells (MSCs) reside [24]. MSCs exist in highly specialized 
microenvironments in which their maintenance, proliferation, migration and 
differentiation involve a complex interplay of many local and systematic signals 
between MSCs and adjacent cells [25]. Even in simplified in vitro model systems, the 
molecular and microenvironmental cues which are necessary to induce bone cell 
differentiation have not yet been fully identified. Furthermore, concurrent studies 
have suggested that an activation and chemotactic migration of host MSCs adjacent to 
the defect sites is favourable for bone regeneration [26]. However, the interaction 
between donor cells and host cells, and the recruitment mechanisms of host MSCs to 
osseous defects are not clear and need to be further demonstrated. In addition, the 
differentiation state of the donor cells, which may have significant implications for 
the effectiveness of cell transplantation, has not been sufficiently elucidated. 
 
1.2 Main purpose of this study 
The main purpose of this study is to investigate the interactions between donor cells 
and host cells, and to identify the possible molecular mechanisms in the initiation of 
bone formation upon donor cell implantation, which is essential to developing optimal 
strategies for clinical application of cell-based therapy in bone tissue engineering. 
 
1.3 Questions to be addressed 
1. Do transplanted donor cells play a role in recruiting host MSCs to the 
bone defect sites to initiate osteogenesis? How do donor cells interact 
with host MSCs? 
2. What are the possible regulatory factors from osteogenically 
differentiated MSCs (OMSCs) that lead to the recruitment of host 
MSCs? 
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3. What are the potential signaling pathways involved in the 
communication between donor cells and host cells during osteogenesis? 
 
1.4 Possible outcomes and significance 
Based on earlier attempts to deliver osteoprogenitor cells that are capable of 
responding to the local microenvironment and facilitate new bone formation in a 
robust and rapid fashion, the concept and application of cell-based therapy for bone 
tissue engineering has been emphasized in this project. More knowledge about the 
role of pre-programmed donor cells in bone defects healing, the interaction between 
donor cells and host cells during osteogenesis has been revealed. Furthermore, this 
project is believed to be the first to unveil the possible molecular pathways which may 
induce the host cells’ response to the signals from the implanted exogenous cells, and 
activate the bone repair and regeneration process upon cell implantation. The new 
findings from this project will be of significant use in facilitating the application of 
pre-programmed donor cells and hopefully extend the field of clinical applications of 
cell-based therapy in bone tissue engineering. 
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CHAPTER 2 OVERVIEW OF PROJECT DESIGN  
 
2.1 The effect of pre-programmed donor cells on host cell 
recruitment during osteogenesis 
2.1.1 In vitro cell migration 
In order to investigate the effect of manipulation of donor cells on the motility of 
MSCs, an in vitro migration assay was performed using transwell system. Transwell 
inserts seeded with MSCs were assembled onto the companion plates, which were 
seeded with osteogenically differentiated MSCs (OMSCs) or undifferentiated MSCs. 
After 8 h of incubation, cell motility was quantified by counting the number of cells 
that migrated through the pores in response to different stimulations from the bottom 
companion plates, and the differences were compared between groups. 
 
2.1.2 In vivo host cell recruitment 
Collagen scaffolds carrying OMSCs or MSCs were implanted subcutaneously or into 
skull defects in severe combined immunodeficiency (SCID) mice. After samples were 
harvested and fixed, micro-computed tomography (μCT) scanning was performed to 
reconstruct three-dimensional (3D) images of the implants, and to measure the 
calcification volume for statistical analysis. After samples were processed and 
sectioned, the ectopic and orthotopic osteogenesis was assessed by subsequent 
histological and immunohistochemical (IHC) staining. In situ hybridisation (ISH) 
against human Alu sequences was performed to distinguish donor human cells from 
host mouse cells, and to investigate the recruitment tendency of host cells in different 
microenvironments. The localisation of transplanted human cells identified by the Alu 
probe in both subcutaneous and skull defect scaffolds was observed, recorded and 
analysed.  
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2.2 Possible regulatory factors that lead to the recruitment 
of host cells 
2.2.1 Comparison between OMSCs and MSCs 
In order to unveil the secreted factors from donor OMSCs that may lead to the 
migration of host MSCs, further study in the new bone forming area was performed. 
Triple staining technique revealed that donor OMSCs strongly expressed VEGF, 
which might exert a paracrine effect resulting in host cell recruitment and their 
involvement in new bone formation. This finding formed the foundation for the 
subsequent project development. Alizarin Red S staining was performed to compare 
the mineralization, while real time quantitative-PCR (RT-qPCR) analysis, enzyme-
linked immunosorbent assay (ELISA) and Western blotting analysis were performed 
to compare the VEGF secretion between OMSCs and MSCs. 
 
2.2.2 The in vitro regulatory effect of VEGF  
Indirect co-culture models were applied to study the effect of VEGF derived from 
OMSCs on the motility, the cell morphology and the CXCL12/CXCR4 expression of 
MSCs. In vitro migration assay and real-time xCELLigence system were performed to 
investigate the motility of MSCs in response to different stimulations, and the 
responding cell morphology changes were further examined by fluorescent staining. 
Furthermore, the expression pattern of CXCL12/CXCR4, which is the best known 
axis that contributes to cell migration, was studied extensively and the effect of VEGF 
on cell responses was probed using a specific neutralizing antibody. 
 
2.2.3 The in vivo regulatory effect of VEGF  
The regulatory effect of VEGF on host cell recruitment was examined by the 
application of neutralizing VEGF antibody in vivo, after OMSCs implantation into the 
skull defects in SCID mice. Histological staining and µCT scanning were performed 
to observe the new bone formation. The recruitment of host cells to the bone defect 
sites was monitored by ISH staining. 
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2.3 Potential cell signaling pathways involved in the host 
cell recruitment 
2.3.1 Functional receptors profile  
MSCs were stimulated with different concentrations of VEGF, or conditioned 
medium derived from MSCs (CM
MSC
) or OMSCs (CM
OMSC
) to establish the receptors’ 
activation profile. The functional role of platelet-derived growth factor receptors 
(PDGFRs) was further investigated using phospho-receptor tyrosine kinase (RTK) 
array, Western blotting analysis and in vitro migration assay. 
 
2.3.2 The involvement of cell signaling pathways 
In order to unveil the potential regulatory cell signaling pathway involved in the host 
cell recruitment, MSCs were stimulated in different conditions with or without the 
interference of the dimerization of PDGFRs. The involvement of PI3K/Akt and 
Erk1/2 in OMSCs-induced MSCs migration was monitored by relevant 
phosphorylated antibodies and inhibitors. The time course phosphorylation status of 
the PI3K/Akt signaling pathway was further investigated by Western blotting analysis. 
 
2.3.3 Downstream effectors of the PI3K/Akt signaling pathway 
The stimulatory effect of VEGF secreted from OMSCs on the activation of the 
PI3K/Akt signaling pathway was further investigated by detecting the 
phosphorylation status of the downstream effectors, mTOR, p70
S6K
, and PAK1, by 
Western blotting evaluation of specific antibodies. 
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CHAPTER 3 LITERATURE REVIEW 
 
3.1 Overview 
Tissue engineering is an emerging interdisciplinary field involving principles of the 
life sciences and engineering with the expectation of constructing a biological 
substitute for damaged tissues, both in vitro and in vivo, in order to restore, maintain, 
or improve normal tissue structure and function [27]. Rapid expansion of knowledge 
regarding the potential for tissue engineering, and more specifically progenitor cell-
based tissue engineering, offers new insights to the treatment of an array of diseases, 
such as graft-versus-host disease (GVHD) [28], cardiovascular failure [29, 30], liver 
diseases [31], injury or degeneration of the spinal cord [32, 33], tendon [34], cartilage 
[35], bone [36] and numerous others. Among the aforementioned conditions and 
diseases, bone defects resulting from trauma or pathological and physiological 
resorption represent a significant global health issue that deserves optimal treatment. 
Although many of the conventional modalities for repairing bone defects are able to 
restore certain levels of function, various drawbacks ranging from limited donor tissue 
to procedure-related complications remain a major clinical challenge [7, 37]. Unlike 
traditional surgeries that need to sacrifice tissues from the donor site, the tissue 
engineering approach can achieve the goal of bone repair and regeneration without the 
necessity of donor site morbidity [38]. Recent studies have demonstrated the 
feasibility of generating tissue-engineered bone for repairing bone defects [39-41], 
and the outcomes of ongoing clinical trials are very promising [36, 42, 43]. 
 
The concept of cell-based tissue engineering has fuelled investigations of various 
progenitor cell sources that can be manipulated, either in vitro or in vivo, to repair or 
replace damaged tissues. Given the complex three-dimensional structure of bone 
tissues, cells, extracellular matrix, cell-cell communications, cell-matrix interactions, 
growth factors, cytokines and other cell components have to be combined in a well-
coordinated space- and time-dependent manner to achieve successful results in bone 
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tissue engineering. In the past few years, there have been significant advances in the 
understanding of the molecular mechanisms of cell fate determination, an extremely 
complex process regulated by multi-mutual interplay of signaling pathways [44-47]. 
Therefore, cell-based therapies with potential to stimulate endogenous progenitor cells 
during osteogenesis have become a prime translational goal. 
 
This review focuses on the current status of knowledge as well as the emerging 
challenges in the area of cell-based therapy and potential cell sources related to bone 
tissue engineering. Additionally, the critical role of the transplanted donor cells, the 
regulatory factors, and the cell signaling pathways leading to the recruitment of host 
cells, have been thoroughly reviewed.  
 
3.2 Cell-based therapy for bone defects  
The treatments for a multitude of skeletal deficits arising from tumors, infections, 
trauma, biochemical disorders, and abnormal skeletal development have been 
conducted clinically through the development of surgical techniques for autologous 
bone graft, allogeneic tissue transplantation and the implementation of biocompatible 
materials [48]. However, each of these reconstructive options has its disadvantages. 
The limited availability of autologous bone graft that can be harvested, and 
considerable morbidity at the donor site remains inherent limitations of autologous 
transplantation [49]. Conversely, although the use of allograft or xenograft avoids 
impairments to the donor site, it is sometimes associated with the risks of infection, 
and unfavorable immune response from the host [50, 51]. In addition, certain bone-
substitute materials can lead to poor integration, adverse reactions and eventual bone 
resorption [52, 53]. Recently, encouraging results from in vitro [54] and in vivo [55, 
56] studies, as well as early human clinical applications [57, 58], have aroused intense 
interest in cell-based therapy as an alternative to the traditional techniques for bone 
defect repair and regeneration. 
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Figure 1. Schematic of cell-based therapy strategy. The cell transplantation/delivery strategy 
involves tissue biopsies, ex vivo expansion of cells from the biopsies, and subsequent transplantation of 
the cells into the recipient. Adapted from [59]. 
 
The traditional concept of cell-based therapy involves the harvest of suitable cell 
sources from autologous/allogenic donors, ex vivo cultivation and expansion to a large 
population (Figure 1). These cells are either transplanted back into to the patient by 
injection, or seeded onto a three-dimensional scaffold and then implanted into the 
recipient [60, 61]. Alternatively, the cell-seeded scaffold can be incubated in a 
bioreactor, where the cells are exposed to certain biological, chemical or physical 
stimuli that promote the formation of the appropriate tissue prior to the implantation 
[62, 63]. The rationale for cell-based therapy to induce bone regeneration is based on 
the high osteogenic potency of osteoinductive cells, which may actively induce 
adjacent progenitor cells to form new bone tissue [64]. Recent investigations probing 
progenitor cell populations have produced a large amount of evidence to support the 
clinical viability of cell-based bone tissue engineering [25]. Most of the studies have 
focused on the selection of cell sources that are safe, less costly and more easily 
available. However, a key unresolved question is whether these cells themselves 
participate in the regenerative process mainly by differentiating into osteoblasts or 
facilitating tissue repair through the production of various trophic factors (cytokines) 
that may modulate the host tissue microenvironment. This may facilitate the 
differentiation of resident stem cells and lead to the cell recruitment through blood 
vessels, bringing even more of the host cells to the bone defect sites. Recent research 
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has also revealed that donor cell number [65], nutrition and matrix acidity in the 
recipient site [66, 67] can also have different effects on the regenerative process. 
 
3.3 Cell sources for cell-based bone tissue engineering 
3.3.1 Mesenchymal stromal cell (MSC) 
Regardless of their original sources, stem cells share two characteristic properties. 
Firstly, they have the capacity for prolonged or unlimited self-renewal under certain 
conditions, and secondly they retain the potential to differentiate into a variety of 
more specialized cell types [68]. Undoubtedly, human embryonic stem cells (hESCs) 
are able to differentiate down an osteogenic lineage in an efficient manner and 
maintain an adequate proliferative capacity post-harvest [69]. However, the political 
and ethical issues associated with hESCs have cast a shadow of doubt over their 
realistic potential for implementation in tissue engineering strategies [70]. Thus, 
MSCs have emerged as a promising cell source in the ongoing research of bone tissue 
engineering [71]. Numerous studies have demonstrated that MSCs derived from 
various origins, including skin, hair follicle, periosteum, bone marrow, adipose tissue, 
and umbilical cord blood, are able to differentiate into osteoprogenitors and 
osteoblasts in vitro and in vivo [72-77]. The osteogenic capacity of MSCs can be 
further enhanced by the systemic or local administration of bone morphogenic 
proteins (BMPs) or other osteoinductive biomolecules, either in slow-release systems 
or viral/non-viral based gene delivery systems [78-82]. The addition of supporting 
biomolecules has gained increasing popularity especially when bone repair in older, 
osteoporotic or diabetic individuals is considered, because the differentiation capacity 
of autologous MSCs in these conditions is known to be compromised [83-85]. 
 
Although the initial enthusiasm surrounding MSC-based bone tissue engineering is 
still growing enormously, research towards the goal of defining a cell surface antigen 
profile unique to MSCs has only achieved marginal success. According to various 
research, MSCs express positive for a long list of cell surface markers, such as CD29, 
CD44, CD73, CD90 (Thy-1), CD105, CD117, CD133, CD166 (activated leukocyte-
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cell adhesion molecule, ALCAM), and CD186 [86, 87]. Other markers including Sca-
1 (stem cell antigen-1), SCF R/c-kit (stem cell factor), SH2, SH3, SH4, STRO-1, and 
HLA Class I have also been identified [88-90]. Furthermore, it is generally agreed 
that the immunodepletion of the hematopoietic cells using anti-CD11b, CD34 and 
CD45, forms the fundamental concept for negative selection method of MSCs 
purification [91, 92]. 
 
In addition, the systemic analysis of cell surface molecules of MSCs has revealed that 
MSCs express receptors for numerous extracellular matrix (ECM) proteins including 
collagen (α1β1-, α2β1-integrin), laminin (α6β1-, α6β4-integrin), fibronectin (α3β1-, 
α5β1-integrin) and vitronectin (αvβ1-, αvβ3-integrin) [93-96]. These specific 
expression patterns of adhesion molecules suggest the potential interactions between 
MSCs and other cell types in vivo [97-99]. Owing to the complexity of the stem cell 
niche, the study of dynamic interactions between stem cells and differentiated 
neighbouring cells in their physiological microenvironment has only recently been 
explored [100-103]. Depending on the ECM and signal molecules in the 
microenvironment, MSCs can develop into adipocytes, osteoblasts, chondrocytes, 
myoblasts or other phenotypes [104-107]. However, no single marker has yet been 
identified that definitively delineates MSCs in vivo and hence there is a lack of 
thorough understanding of the mechanisms underlying stem cell renewal and its 
functional differentiation characteristics.  
 
3.3.2 Bone marrow stromal cell (BMSC) 
The first MSC population to gain significant attention from researchers and provide 
the largest contribution to the current knowledge regarding the osteogenic potential of 
MSCs is derived from the bone marrow cavity, which is in tight contact with the 
hematopoietic compartment [108]. Bone marrow stromal cells (BMSCs) have been 
identified as a population of organized hierarchical postnatal stem cells with the 
potential to undergo osteogenic, as well as chondrogenic and adipogenic 
differentiation when exposed to appropriate microenvironmental cues [76].  
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Because of their multipotent nature, BMSCs have become one of the most important 
cell sources for cell-based therapy and tissue regeneration [109]. Their osteogenic 
differentiation potential has been well characterised in many in vitro studies [110-
112]. In addition, animal model-based studies also reveal that BMSCs have 
significant capability for healing bone defects of critical size in vivo when implanted 
with proper biomaterials [113, 114], indicating their great potential for bone tissue 
engineering applications. In terms of human studies, the use of in vitro expanded 
autologous BMSCs in conjunction with porous hydroxyapatite ceramic scaffolds has 
been reported in the treatment of large bone defects [115]. Progressive integration of 
the implants with the native bone was observed as well as new bone formation inside 
the bioceramic pores and vascular ingrowth. A favorable integration of the implants 
with the pre-existing bone was maintained during the long-term follow-up period and 
no major adverse reactions were found, illustrating the durability achieved by the cell-
based bone tissue engineering approach [116]. 
 
Osteogenic induction may enhance the probability of in vivo bone formation and 
contribute to the reliability of bone tissue engineering. Several recent investigations 
demonstrated that in vitro osteogenic induction of BMSCs before implantation could 
significantly promote subsequent ectopic bone formation compared to 
undifferentiated BMSCs [19]. Therefore, it may be feasible to obtain a relatively 
small amount of autologous BMSCs from patients, expand and pre-differentiate them 
into an appropriate number of osteoblastic cells and implant them back to the donors 
to facilitate the repair and regeneration of bone defects. Recent research has also 
addressed the importance of a proper microenvironment for BMSC transplantation 
[117]. It is hypothesized that injured tissues produce the appropriate signals necessary 
for cell transplantation and that the local microenvironment may eventually induce 
particular phenotypes and functions of the transplanted cells [118-120]. However, the 
specific microenvironment (i.e., the unique combination of matrix, growth factors, 
and cell adhesion cues), which is critically important for the control of progenitor cell 
maintenance, proliferation, and differentiation, and is required to determine the final 
fate of the transplanted BMSCs in vivo, remains unknown.  
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3.3.3 Osteoblast (OB)  
Understanding bone growth regulation, the continued remodeling of bone throughout 
life, and the regeneration of injured tissues are the basic biological concerns of 
clinicians for the treatment of skeletal diseases. The major event that triggers 
osteogenesis is the transition of MSCs into bone forming osteoblasts (OBs). OBs are 
mononuclear, not terminally differentiated cells that are responsible for the synthesis, 
deposition and mineralization of ECM. Therefore, they play a pivotal role in creating 
and maintaining skeletal architecture. MSCs need to undergo several transitional steps 
before becoming mature OBs. Each transition requires complex activation or 
suppression of critical molecular elements for the commitment and differentiation of 
OBs to occur (Figure 2).  
 
 
Figure 2. Schematic of osteoblast differentiation. Adapted from [121]. 
 
Over the last decade, molecular and genetic studies have broadened our understanding 
of OB differentiation. Ducy and Karsenty conducted the initial study on the regulation 
of osteocalcin, which is the most specific gene of OBs [122]. The earliest 
osteoprogenitor cells express Runt-related transcription factor 2 (RUNX2), a bone 
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specific transcription factor, which is required for the early stages of OB 
differentiation [123]. Osteoblastogenesis consists of three major stages, proliferation, 
matrix maturation, and mineralization, which are characterised by sequentially 
expressed distinctive markers from OBs. Alkaline phosphatase (ALP), type I collagen 
(COLI), osteocalcin (OCN), osteopontin (OPN) and PTH-related protein (PTHrP) 
receptor are the most frequently used markers during osteoblastogenesis [124, 125]. 
Generally, ALP and COLI are early markers of OBs’ differentiation, while OCN and 
PTHrP receptors appear late. OPN reaches its peak during proliferation and in the 
later stages of differentiation. 
 
Following the initial lineage commitment, there is a phase of expansion. The initial 
cell division is asymmetric, giving rise to another stem cell and a committed 
osteoprogenitor. The pre-osteoblasts are at an intermediate stage. They still proliferate 
and then develop into OBs that synthesize bone matrix. The mature OBs lie adjacent 
to the newly formed osteoid and express ALP, OPN, BSP, and OCN. The cumulative 
effect of the recruitment of stem cells and their expansion, and the functional capacity 
of mature OBs, are measured by rates of bone formation in vivo. There are three fates 
upon completion of the synthetic phase in the terminal stage of the remodeling cycle. 
OBs may become osteocytes upon entrapment within the mineralized matrix, evolve 
into inactive lining cells that protect the bone matrix from osteoclasts, or undergo 
apoptosis [126].  
 
Immature OBs derived from MSCs may provide more consistency in forming bone 
than precursor populations with multipotentiality in terms of cell-based therapy for 
bone defect healing [127, 128]. However, the isolation procedure of OBs is 
considerably labour-intensive and time consuming. In addition, only a relatively small 
number of cells are available after the dissociation of the tissue and their expansion 
rates are comparatively low. Consequently, the generation of clinically adequate 
numbers of OBs for cell-based therapy is a significant challenge.  
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3.4 The contribution of donor cells in cell-based bone tissue 
engineering 
Although the outcome of cell-based therapy using the aforementioned cell sources has 
been encouraging, the precise mechanisms by which the donor cells enhance tissue 
repair and regeneration are not clearly understood. In most cases, the intent of cell-
based therapy is to repair damaged tissues with donor cells capable of carrying out 
structural and functional recovery [128]. However, the extent of donor cell 
contribution to the   cells/tissues of interest has not been fully elucidated. It becomes 
apparent that in many situations, the donor cells improve tissue regeneration at the site 
of damage without significant engraftment or differentiation [129]. Studies in which 
MSCs were transplanted into children with severe forms of osteogenesis imperfecta 
(OI) revealed the level of donor cell engraftment was extremely low and could not 
justify the growth acceleration and the bone fracture rate reduction [130-132]. In other 
related studies, transplantation of BMSCs into animal models of myocardial infarction 
(MI) led to significantly improved cardiac function due to the secreted factors from 
donor cells, rather than direct engraftment or differentiation [133, 134]. These 
findings lead to the speculation that besides direct cell-to-cell contact, the donor cells 
may secrete proinflammatory cytokines (such as IL-1 and IL-6), mitogens (such as 
IGF, FGF and PDGF), morphogens (BMPs), and angiogenic factors (VEGF and 
angiopoietins) [135, 136], which exert paracrine activities and modulate the 
microenvironment for neighboring stem cells to carry out the reparative process [137-
140]. In addition, the broad spectrum of bioactive molecules that are produced by the 
donor cells may lead to the tropism of endogenous cells from their original niches.  
 
In the field of cell-based bone tissue engineering, a recent study from Cancedda’s 
team has shed some light on the commitment of donor cells by using a murine model 
of ectopic bone formation. This particular study demonstrated that the origin of newly 
formed bone was dependent on the maturation status of the implanted cells [141]. An 
intramembranous ossification directly performed by the donor cells was observed 
when mature OBs were seeded onto a porous ceramic. In contrast, the implantation of 
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undifferentiated MSCs led to the formation of new bone of host origin via 
endochondral ossification. Researchers have also shown that MSCs are able to 
accelerate the wound healing process by stimulating cell differentiation [142], and 
releasing pro-angiogenic factors that promote new blood vessel formation [143]. The 
newly formed vasculature is not only critical for the transportation of oxygen and 
nutrients to the centre of the implants, but also fundamental to the recruitment of host 
cells through the connection with the host circulating system. This creates a 
communicative network between the recipient organism and the engineered graft. In 
addition, the implanted cell/scaffold constructs may create a transient inflammatory 
microenvironment, in which an innate response is mediated by a mixed cell 
population, mainly composed of the recruited monocytes, macrophages, and 
lymphocytes. The released factors from the inflammatory cells in turn act as signals 
and impact on the way donor cells contribute to the tissue repair and regeneration 
process in vivo [144-146]. In this respect, although the molecular mechanisms are yet 
poorly understood, it is reasonable to hypothesize that donor cells can act indirectly as 
“signaling centres”, orchestrating the host response to the skeletal defects, in addition 
to their direct role as osteoprogenitors and osteoblasts. 
 
3.5 The involvement of host cells in cell-based bone tissue 
engineering 
There is no doubt that cell-based therapy is becoming one of the most promising 
strategies to repair irreversibly-affected tissues. However, the therapeutic efficacy 
may not only depend on the involvement of donor cells, but also the activation and 
homing of endogenous cells from their original niches through the circulation to the 
injured tissues. Within a complex niche, endogenous cells are exposed to a variety of 
spatially and temporally controlled biochemical mixtures of insoluble transmembrane 
receptor ligands, proteases, adhesion molecules (such as selectins and integrins), 
ECM molecules, as well as soluble chemokines, cytokines and growth factors [147, 
148]. In the field of stem cell biology, the term “homing” is often defined as the 
recruitment of endogenous cells to the damaged tissues or their navigation to other 
targeted anatomic destinations following mobilization [149], often over great 
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distances via the bloodstream. In addition, a highly proliferative population of 
progenitor cells residing in the neighboring healthy tissues may also be recruited to 
the defect sites [59] (Figure 3). 
 
 
Figure 3. Schematic of endogenous cells homing to the damaged tissues for in situ 
tissue regeneration. The homing of endogenous cells involves actively recruiting host stem cells 
from either the blood or a tissue specific niche to the site of injury. Adapted from [59]. 
 
Host cell mobilization is not only essential in a wide range of physiological and 
pathological phenomena, but also important to biotechnological applications such as 
regenerative medicine and tissue engineering. Previous work has demonstrated that 
endogenous biological resources and environmental conditions can be used for in situ 
tissue regeneration, suggesting the possibility to reduce the intensive labour for donor 
Exit tissue 
niche to 
enter blood 
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cell procurement and manipulation [150]. Applications of in situ tissue regeneration 
are primarily based on the local release of bioactive molecules, such as cytokines and 
growth factors, to enhance the mobilization of host cells and control the fate of the 
recruited endogenous cells for efficient tissue regeneration. Mao and colleagues have 
successfully fabricated a TGFβ3-infused scaffold which could induce homing of 
endogenous cells to regenerate the entire articular surface of the rabbit synovial joint 
[151]. A more recent study instead emphasized the efficiency of combined systemic 
and local delivery of stem cell recruiting factors for tissue engineering, showing that 
the combined system could significantly enhance the recruitment of host cells which 
were capable of differentiating into multiple lineages [152].  
 
Likewise, in cell-based bone tissue engineering, a continuous source of cell 
recruitment to the bone defect site is ensured by the endogenous cells. The research 
by Tasso and coworkers showed that two consecutive waves of host cell migration 
were induced by the donor cells seeded on the porous ceramic scaffolds [153]. The 
first wave, observed 7 days after the implantation, was enriched in CD31
+
 endothelial 
cells, whereas the second wave, observed at day 11, was enriched in CD146
+
 
perivascular cells, potentially responsible for the newly formed bone. Another study 
has also demonstrated that osteoblastic precursors can be systemically recruited from 
remote bone marrow cavities via the bloodstream and become involved in fracture 
healing [154]. 
 
The full comprehension of the host response to implanted donor cells is of great 
importance to the development of novel clinical strategies where host cells could 
contribute to regenerate the appropriate tissue. What remains unclear is the 
mechanism of how the endogenous cells are recruited to the damaged 
tissue/transplantation site, and what potential role the recruited host cells play in the 
process of tissue repair and regeneration. Therefore, it is necessary to further 
understand the phenomenon of host/donor cells interaction, which may benefit the 
optimization of treatment alternatives for nonunion fractures and other pathologic 
skeletal deficits. 
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3.6 Chemokines and growth factors related with cell 
migration 
Cell migration is a fundamental component of embryogenesis, vasculogenesis, wound 
healing, immune surveillance, as well as tumor cell metastasis. It is a mechanically 
integrated molecular process regulated by a series of coordinated mechanisms [155]. 
Cells become asymmetrical and polarized during migration, with front and back ends 
formed to direct movement [156]. Broad lamellipodia and spike-like filopodia take 
place primarily around the cell front, whereas, stress fibers, which are involved in cell 
adhesion, are formed or deformed at the back [157]. These multi-step processes 
involve morphological changes that result from the rearrangement of actin 
cytoskeleton, the emergence of protrusive membrane structures followed by the 
contraction of the cell body, the detachment of the uropod and the secretion of matrix 
degrading enzymes [157, 158]. A multitude of chemokines, cytokines and growth 
factors play critical roles in regulating the mobilization and homing of MSCs for 
effective regeneration of functional tissue. 
 
3.6.1 CXCL12 
Chemokines (Chemotactic cytokines) are a family of small (8-10 kDa) proteins able to 
chemically direct responsive cells, such as lymphocytes, neutrophils, hematopoietic 
cells and other cell types to the targeted tissue compartment [159]. In addition, 
chemokines are thought to play an important role in cell activation, differentiation and 
survival [160-162]. Members of the chemokines are divided into four subfamilies, 
namely CXC, CC, C and CX3C chemokines, depending on the spacing of their first 
two cysteine residues [159, 163]. Of these, CXC and CC chemokines are the two 
major groups.  
 
Chemokine (C-X-C motif) ligand 12 (CXCL12) is the most predominant stem cell 
homing factor to date [164]. It was first identified as stromal cell-derived factor-1 
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(SDF-1) in the supernatant of BMSCs [165]. CXCL12 is strongly expressed in bone 
marrow and produced by osteoblasts, endothelial cells and reticular cells that are 
scattered through the bone marrow stroma [166]. CXCL12 is highly conservative and 
has 99% homology between mouse and human, allowing CXCL12 to act across 
species barriers. Upon stimulation with CXCL12, MSCs are able to rearrange the 
actin cytoskeleton and increase phosphorylation of the focal adhesion adapter protein 
paxillin, which is required for focal adhesion turnover and ultimately migration [167]. 
The critical role for CXCL12 in the homing of endogenous cells to damaged sites has 
been unraveled by studies in animal models of liver, limb, and heart damage [168-
171]. One of the most important functions of CXCL12 is related to tissue repair and 
regeneration. Recent investigations have shown the repair of ischemic injuries 
involves the selective recruitment of circulating or resident progenitor cells. Hypoxia-
inducible factor-1 (HIF-1), a central regulator of tissue hypoxia, induces CXCL12 
expression in ischemic areas in direct proportion to reduced oxygen tension in vivo 
[172, 173]. The elevated CXCL12 then recruits the circulating progenitor cells to 
repair the damaged tissues.  
 
Chemokine (C-X-C motif) receptor 4 (CXCR4) is the best characterised receptor for 
CXCL12 and an essential mediator for the chemotaxis responses induced by CXCL12 
in many responsive cells [174]. Previous studies have shown the CXCR4-deficient 
mice died in utero or perinatally due to multiple defects in developing hematopoietic 
and nervous system [175-177], leading to the conclusion that CXCR4 is indispensible 
to several physiological processes during late embryonic and early postnatal stages. A 
recent study has also provided evidence that CXCR4 functions in postnatal bone 
development by regulating OB development in cooperation with BMPs signaling, 
indicating CXCR4 acts as an endogenous signaling component necessary for bone 
formation [178]. In bone marrow, CXCL12 availability has been shown to be 
regulated by the uptake of CXCL12 via CXCR4 positive cells, which then translocate 
the chemokine into the bone marrow. This transporter function is characteristic of 
both endothelial and stromal cells [179]. The binding of CXCL12 to CXCR4 leads to 
receptor structural changes and G-protein activation, which then stimulates signaling 
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cascades (e.g., PI3K and MAPKs), and induces intracellular Ca
2+ 
release, resulting in 
cell migration, proliferation and survival (Figure 4).  
 
The interaction of CXCL12 with CXCR4 is thought to regulate trafficking of the 
hematopoietic stem cells, endothelial progenitor cells (EPCs) and in prostate and 
breast cancer metastasis to bone and lung [180, 181]. The pivotal role of the 
CXCL12/CXCR4 axis in the mobilization and homing of stem cells to injured or 
stressed tissue is further investigated by numerous researchers [182-184]. Previous 
work has demonstrated that applying a neutralizing CXCR4 antibody after induction 
of cerebral ischemia in a rat model compromised BMSC homing, resulting in poor 
neurological recovery after stroke [185]. On the other hand, transfection or 
transduction of MSCs with CXCR4 is reported to enhance cell migration toward 
CXCL12 in vitro [186, 187] and toward infracted myocardium in rats [188], whereas 
almost no migration is observed to normal myocardium [188]. Recent studies have 
emphasized the clinical effect of CXCR4 antagonist. The bicyclam AMD3100, also 
known as Plerixafor (Mozobil™), is a competitive selective CXCR4 antagonist. It 
blocks the binding of CXCR4 to CXCL12 and has been demonstrated to interfere 
with a number of pathophysiological processes [189], such as rheumatoid, allergic 
and malignant diseases. Physiologically, bone marrow has a higher CXCL12 
concentration than any other tissues, therefore, circulating MSCs home to bone 
marrow proficiently. AMD3100 has been shown to mobilize CD34
+
 stem cells from 
the bone marrow into the blood circulation and augment the migration of bone 
marrow-derived EPCs into sites of neovascularization after myocardial infarction 
[190]. Currently, AMD3100 is actively pursued as a stem cell mobilizer for 
autologous transplantation in patients with multiple myeloma and non-Hodgkin's 
lymphoma [189], and has great potential for the treatment of other hematological 
malignancies and non-hematological malignancies. 
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Figure 4. CXCL12/CXCR4 signaling pathway. Binding of CXCL12 to CXCR4 leads to 
receptor structural changes and G-protein activation. Activated G-proteins induce multiple signaling 
pathways, such as PI3K, MAPKs and NFκB, and the release of intracellular Ca2+. These signaling 
pathways are associated with cell proliferation, migration and survival.  
 
3.6.2 VEGF  
As most members from the VEGF/platelet-derived growth factor (PDGF) family, 
VEGF is the potent mitogen for endothelial cells (ECs), and one of the key regulators 
of angiogenesis, vasculogenesis and developmental hematopoiesis. In addition to its 
well-documented effects on blood vessel development and formation [191, 192], 
VEGF also plays a critical role in promoting osteogenesis [193]. VEGF is of great 
importance for the patterning of the bone growth plate [194, 195] by stimulating the 
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differentiation of OBs [196] and the crosstalk between OBs and ECs [197]. In a 
mouse femur fracture study, treatment with exogenous VEGF enhanced not only 
blood vessel formation but also ossification and new bone formation, whereas VEGF 
inhibition impaired callus mineralization [198]. Various cell types secrete VEGF, 
including tumor cells, macrophages, OBs and osteoblast-like cells, and several growth 
factors, hormones, and cytokines regulate its expression. It has been demonstrated that 
VEGF secretion from osteoblastic cells is at low levels in the early stage of osteogenic 
differentiation [199] and markedly increases as osteoblastogenesis proceeds [200]. 
This is significantly regulated by OB-specific transcription factor Osterix, as reported 
in a recent study [201]. Interestingly, VEGF has been proved to be chemoattractive 
for primary human osteoblasts, providing first evidence that it may also be involved in 
local recruitment of osteoprogenitor cells in the course of endochondral bone 
formation or remolding [202, 203].  
 
There are five structurally related mammalian VEGF ligands, namely, VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF) [204]. Each VEGF 
ligand has several different variants due to either alternative splicing or processing. 
Being the most abundant and active member of the VEGF family, VEGF-A 
undergoes alternative splicing, which results in at least six isoforms (VEGF-A121, 
VEGF-A145, VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A206), among which 
VEGF-A165 is the most predominant and biologically potent. The VEGFs are 
produced by many different cell types and typically act locally in a paracrine manner. 
However, VEGF-A produced by ECs may act in an autocrine manner to stimulate 
vessel survival [205].  
 
The VEGFs bind to three structurally related VEGFR tyrosine kinases, VEGFR-1 
(Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4), each of which forms a 
homodimer on ligand binding [206] (Figure 5). VEGF-A binds to VEGFR-1 and 
VEGFR-2, but not VEGFR-3. The majority of VEGF signaling is mediated through 
VEGFR-2 in endothelial cells [206, 207]. VEGF-A165 can also interact with 
neuropilin-1 (NRP-1) and neuropilin-2 (NRP-2), which are cell surface 
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transmembrane glycoprotein receptors [208]. NRPs have a short cytoplasmic domain, 
thus it is speculated that they do not mediate the signal independently, but function 
only as co-receptors [208]. It has been reported that NRP-1 can associate and form a 
complex with VEGFR-2, leading to an enhanced VEGFR-2 signaling induced by 
VEGF-A165 binding to NRP-1 [209]. One interesting finding is that VEGF-A can 
stimulate MSCs proliferation and mobilization to damaged tissues by binding to and 
activating PDGF receptors, even though MSCs express low basal level of VEGFRs 
[210].  
 
 
Figure 5. Vascular endothelial growth factor (VEGF) family members and their 
receptors. The mammalian VEGF family consists of five structurally related glycoproteins, VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF). The VEGFs bind to three 
structurally related VEGFR tyrosine kinases. VEGF-A binds to both VEGFR-1 and VEGFR-2. VEGF-
B and PlGF bind exclusively to VEGFR-1. VEGFR-3 is a specific receptor for VEGF-C and VEGF-D. 
VEGF-C and VEGF-D can be proteolytically processed to allow binding to VEGFR-2 as well. In 
addition, neuropilin (NRP)-1 and NRP-2 act as co-receptors for specific isoforms of VEGF family 
members, and increase the binding affinity of these ligands to their respective receptors. Adapted from 
[211]. 
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3.6.3 PDGF  
PDGFs are the primary mitogens for the cells of mesenchymal and neuroectodermal 
origin and are members of the evolutionarily conserved, structurally and functionally 
related VEGF/PDGF family [212]. First identified in 1970s as a serum growth factor 
that stimulates proliferation of fibroblasts, smooth muscle cells (SMCs) and glial cells 
[213-215], the PDGF family is now one of the best characterised growth factor 
systems.  
 
The PDGF family consists of four different isoforms, the traditional PDGF-A and 
PDGF-B, and more recently discovered PDGF-C and PDGF-D [216]. PDGF-A and 
PDGF-B are processed intracellularly and are secreted in their active forms, while 
PDGF-C and PDGF-D are secreted as latent factors and require extracellular cleavage 
of the CUB domain. This is carried out by the tissue-type plasminogen activator (tPA) 
for PDGF-C, and the urokinase-type plasminogen activator (uPA) or matriptase for 
PDGF-D [217-220]. The PDGF ligands exist as disulphide-bonded polypeptide chains, 
including the four homodimers PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD, 
and one heterodimer, PDGF-AB [221]. The ligands exert their biological activities via 
two distinct but structurally related, membrane bound receptor tyrosine kinases 
(RTKs), PDGF receptor-α (PDGFR-α) and PDGF receptor-β (PDGFR-β). Particularly 
strong expression of PDGFR-α has been noticed in subtypes of mesenchymal 
progenitors in lung, skin and intestine, as well as in oligodendrocyte progenitors, 
while PDGFR-β is expressed in the mesenchyme, especially in vascular SMCs 
(vSMCs) and pericytes [222]. Ball et al. also reported that MSCs in vitro have a high 
cell surface ratio of PDGFR-α/PDGFR-β [223], and PDGFR-α appears to be a 
characteristic of undifferentiated MSCs. The PDGFRs have common domain 
structures, including five extracellular immunoglobulin (Ig) loops and a split 
intracellular tyrosine kinase domain [222]. The binding of ligand to the receptor 
triggers receptor homodimerization or heterodimerization, resulting in 
autophosphorylation of specific tyrosine residues within the intracellular domains and 
kinase activation. Once activated, intracellular mediators dock to phosphotyrosine 
residues in the receptor, leading to the activation of downstream signaling pathways, 
e.g. PI3K, MAPK and PLC-γ. The ability of each of the five dimeric PDGF ligands to 
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bind and activate the PDGF receptors is quite specific as summarized in Figure 6. 
PDGF-AA can only interact with PDGFR-α, whereas PDGF-BB has a greater binding 
affinity for PDGFR-β. However, PDGFR-β is also capable of binding PDGFR-α, and 
thus can induce all three receptor homodimer and heterodimer. PDGF-AB and PDGF-
CC can both bind to PDGFR-α, and initiate the formation of homodimer and 
heterodimer. PDGF-DD binds predominantly to PDGFR-β and forms a homodimer 
PDGFR-ββ, but also may induce lower levels of the heterodimeric PDGFR-αβ [222, 
224].  
 
Figure 6. Simplified schematic of the platelet-derived growth factor (PDGF) system. 
PDGF-A and-B are secreted as active homo- or heterodimers. PDGF-C and –D are secreted as 
homodimers and latent factors which need extracellular cleavage of the CUB domain by tPA (PDGF-
C), uPA (PDGF-D) or matriptase (PDGF-D) for receptor binding and activation. PDGF-AA is the most 
selective member of the PDGF family and activates PDGFR-αα exclusively. PDGF-BB is the universal 
ligand. PDGF-AB and PDGF-CC assemble and activate PDGFR-αα and PDGFR-αβ. PDGF-DD 
activates PDGFR-ββ, and under certain circumstances, PDGFR-αβ. PDGF binding results in 
autophosphorylation and activation of different signaling pathways, such as JAK/STAT, PI3K, PLC-γ 
or MAPK. Downstream signaling promotes gene expression and mediates the biological functions of 
the PDGF isoforms, e.g. proliferation, migration, and survival. Adapted from [225]. 
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Since being originally isolated due to its ability to promote cell proliferation, PDGF 
has been appreciated to initiate additional cellular responses such as cell survival and 
migration. PDGF signaling is undoubtedly required for the spreading of various 
populations of cells during embryonic development, such as oligodendrocyte 
precursors in the spinal cord, neural crest mesenchymal cells toward the branchial 
pouches and cardiac outflow tract, and pericytes along newly formed angiogenic 
sprouts [222]. The mechanisms by which PDGF regulates the process of cell 
spreading remain largely undefined in most of the situations. However, recent studies 
in Drosophila, Xenopus, and mouse have demonstrated a role for PDGF family 
members in directed cell migration in certain developmental processes in vivo. PDGF-
AA induced chemotaxis is well documented [226], and PDGFR-α promotes a 
chemotactic response in various cell types [227]. Nagel et al. demonstrated PDGF-
A/PDGFR-α signaling is required for directional migration of mesoderm on its 
endogenous matrix substratum, as well as for cell orientation in the embryo [228]. 
Knockout of the genes encoding PDGFR-β or PDGF-B in mice causes deficient mural 
cell recruitment, leading to widespread microvascular bleeding [229-231]. PDGF-BB, 
the main ligand of PDGFR-β, is a potent stimulant of SMCs recruitment during 
neointimal hyperplasia following vascular injury [222]. PDGFR signaling has also 
emerged as a predominant pathway in the recruitment of perivascular MSCs, which 
play fundamental roles in angiogenesis, wound repair and tissue regeneration [210, 
232-234]. A recent study has further identified the synergistic relationship between 
α5β1-integrin and PDGFR-β. Cell adhesion to fibronectin induced PDGFR-β 
phosphorylation in an α5β1-integrin dependent manner, leading to the activation of 
the PI3K/Akt pathway, actin reorganization and recruitment of MSCs [235]. 
 
3.7 Signaling pathways related with cell migration 
In order to participate in tissue repair and regeneration, MSCs have to be mobilized 
and migrate to the target sites and integrate with the local tissues. Understanding the 
potential signaling pathways in relation to the endogenous cell homing can offer new 
insights into the management of bone defect healing. 
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3.7.1 PI3K/Akt signaling pathway  
Phosphoinositide 3-kinases (PI3Ks) were initially discovered as lipid kinases 
associated with viral oncoproteins about 20 years ago [236]. Since then, the 
association between PI3Ks and cancer has been further elucidated [237]. Over the last 
decade, growing evidence has indicated that preferential activation of PI3Ks is 
important for defining the leading edge in a wide range of motile cell types [238-240]. 
PI3K has been the focus of attention with respect to its activation by chemokine 
receptors and the role it plays in regulating cell migration [241, 242]. The PI3K 
family can be divided into three main classes according to their in vitro lipid substrate 
specificity, enzyme structure and products formed [243]. The heterodimeric class I 
PI3Ks consist of two structurally closely related subgroups. Class IA enzymes share 
one of the common regulatory subunits (p85α and -β, p50α, and p55α and -γ) and 
different catalytic subunits (p110α, -β, and -γ) [244]. Class IB enzymes comprises a 
p101 or p84 regulatory subunit as well as the p110γ catalytic isoform [245, 246]. 
Classes IA and IB are the most extensively studied PI3Ks and, together with their 
lipid product phosphatidylinositol (3,4,5)-triphosphate (Ptdlns(3,4,5)P3), have been 
widely implicated in controlling cell migration and polarity [247] (Figure 7). Class II 
PI3Ks lack a regulatory subunit and contain three isoforms (C2α, -β, and -γ), which 
are capable to phosphorylate Ptdlns and Ptdlns(4)P to Ptdlns(3)P and Ptdlns(3,4)P2, 
respectively. Recent studies have suggested that class II PI3Ks may play a positive 
role in the regulation of cell adhesion and actin reorganization during cell migration 
and wound healing in non-immune cell systems [248, 249]. The sole member of class 
III PI3K is vacuolar protein sorting 34 (Vps34), which consists of a regulatory subunit, 
p150, for its activity. Vps34 produces only Ptdlns(3)P from Ptdlns and is involved in 
multiple steps of membrane trafficking. However, no defined role of Vps 34 in cell 
migration has been reported so far [250]. 
 
29 | P a g e  
 
 
Figure 7. Signaling through phosphatidylinositol (3,4,5)-triphosphate. On stimulation of 
class I PI3Ks together with their lipid product phosphatidylinositol-3,4,5-trisphosphate 
(Ptdlns(3,4,5)P3), several phosphatases are involved in subsequent dephosphorylation steps (dashed 
arrows). PTEN hydrolyses the 3-phosphate of Ptdlns(3,4,5)P3 to regenerate phosphatidylinositol-4,5-
bisphosphate (Ptdlns(4,5)P2), thus terminating PI3K signaling. 5-phosphatases such as SHIP, however, 
generate Ptdlns(3,4)P2 that, like Ptdlns(3,4,5)P3, can facilitate the activation of Akt. The key reaction 
steps outlined are integrated into complex signaling networks in which Akt and other targets of 3-
phosphorylated phosphoinositides, together with further downstream components, regulate cell growth, 
proliferation, survival and motility. Adapted from [251]. 
 
The serine/threonine kinase Akt, also known as protein kinase B (PKB), is the best 
characterised downstream effector of class І PI3Ks. The Akt family consists of three 
isoforms, namely Akt1 (PKBα), Akt2 (PKBβ) and Akt3 (PKBγ). They are expressed 
ubiquitously, share similar activation mechanisms and typically initiate signal relay to 
secondary signaling cascades by phosphorylating an overlapping subset of particular 
proteins [252]. Akt has emerged as one of the key regulators for cell survival, 
proliferation, angiogenesis and glucose metabolism [253-256]. A growing body of 
evidence indicates that Akt may also affect cytoskeletal changes and promote cell 
migration in different organisms [257-260]. However, the role of isoform-specific Akt 
family members in the regulation of cell migration has been difficult to ascertain. 
Activation of Akt1 has been found to negatively influence mammary epithelial cell 
migration and epithelial-mesenchymal transition (EMT) [261], whereas siRNA 
knockdown of Akt1, but not Akt2, results in a considerable increase in cell migration, 
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which was related to the activation of extracellular-signal-regulated kinase-1 and -2 
(ERK1/2) [261]. The inhibitory effect of Akt1 on cell motility and invasion has also 
been investigated in various breast cancer cell lines, in which degradation of the 
nuclear factor of activated T cells (NFAT) transcription factors was involved [262]. 
On the contrary, other reports have claimed a distinctive role of Akt1 in promoting 
cell migration and invasion [263, 264]. Similarly, the positive effect of Akt2 on cell 
motility has been well established. Recent investigations have demonstrated that the 
reduction of Akt2 inhibits chemotaxis signal transduction in glioma cells [265] and 
breast cancer cells [266]. On the other hand, Akt2 has been found to be a negative 
regulator of Pak1 [267]. Akt2 knock-out mouse embryonic fibroblasts have increased 
migration, especially invasion through ECM, suggesting a negative role of Akt2 in 
regulation of Rac/Pak signaling, the actin cytoskeleton and cell migration [267]. 
Interestingly, an inhibitory role for both Akt1 and Akt2 in prostate cancer migration 
and invasion has been reported in a recent study [268]. However, the inconclusive 
effects of Akt1 and Akt2 on cancer cell migration may not translate to other cell types. 
These studies demonstrate the importance of crosstalk between the PI3K/Akt pathway 
and other pathways and highlight the cell type-specific actions of Akt kinases in the 
regulation of cell motility. 
 
Several PI3K/Akt stimulators have been documented to enhance cell migration [269-
272]. The role of CXCL12, one such stimulator, in cancer cell invasion has been well 
studied. Binding of CXCL12 to CXCR4 leads to the stimulation of a signaling 
cascade that involves activation of multiple targets, including ERK1/2, p38 and Akt 
[273-276]. It has been reported previously that CXCL12 could stimulate a rapid and 
transient accumulation of PtdIns(3,4,5)P3 in leukaemic T cell lines and peripheral 
blood-derived lymphocytes within 15 sec, and the elevated accumulation returned to 
basal level 5 min after chemokine treatment [277]. Other work has further 
demonstrated the cell migration induced by CXCL12 can be abrogated by the PI3K 
inhibitors wortmannin and LY294002 [241, 242, 273]. Hypoxia pre-conditioning has 
also been shown to enhance MSCs migration and improve their tissue regenerative 
potential via the activation of the PI3K/Akt signaling pathway [278]. 
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A number of phosphorylation targets for Akt are now emerging. Enomoto and 
colleagues have recently identified a novel substrate of Akt, designated Girdin 
(girders of actin filaments), which is an actin binding protein [279]. The accumulation 
of phosphorylated Girdin at the leading edge of migrating cells suggests that Girdin is 
essential for the remodeling of the actin cytoskeleton that propels the cells forward 
and provides a direct link between Akt and cell motility [279, 280]. The p70 S6 
kinase (p70
S6K
) is also a downstream effector of the PI3K/Akt pathway, which 
regulates cytoskeleton dynamics via the actin filament cross-linking proteins. The 
overexpression of p70
S6K
 in ovarian cancer cells has been reported to induce a marked 
reorganization of the actin cytoskeleton and promote directional cell migration [281]. 
Researchers have demonstrated that p70
S6K
 can stimulate the rapid activation of Rho 
family small GTPases Cdc42 and Rac1, as well as their major downstream effector, 
p21-activated kinase 1 (PAK1) [281, 282]. PAK1 is the first discovered member of 
the mammalian PAK family, which comprises six proteins divided in group І (PAK1-
3) and group II (PAK4-6) according to their structural and functional features [283, 
284]. PAK1 plays a fundamental role in controlling cell motility by linking a variety 
of extracellular signals to changes in actin cytoskeleton organization, cell shape and 
adhesion dynamics [285-287]. 
 
3.7.2 MAPK signaling pathway  
Mitogen-activated protein kinases (MAPKs) belongs to a large family of highly 
conserved serine/threonine protein kinases, which are found in all eukaryotic cells, 
and expressed in virtually all tissue types. To date, six distinct classes of MAPKs have 
been characterised, namely, the extracellular signal-regulated kinases (ERK) 1 and 2 
(ERK1/2), ERK3/4, ERK5, ERK7/8, p38 (α/β/γ/δ) MAPK, and c-Jun N-terminal 
kinases (JNK1/2/3) [288-290]. JNK1/2/3 and p38 (α/β/γ/δ) MAPK are collectively 
called stress-activated protein kinases (SAPK). ERK5 is also known as big MAPK 
(BMK1) [291, 292]. Very little is known about the atypical MAPK enzymes, ERK3/4 
and ERK7/8. However, all the members of MAPKs consist of a homodimer of 
molecular mass of about 80 kDa and contain the signature sequence T–X-Y, where T 
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and Y are threonine and tyrosine, and X denotes glutamate in ERK, proline in JNK, 
and glycine in p38, respectively [293, 294]. 
 
MAPKs are pivotal components of a complex intracellular signal transduction 
pathway that functions to integrate the cells’ response to extracellular stimuli (Figure 
8). The activation of MAPKs proceeds through a series of upstream molecules in an 
orderly fashion. Various extracellular stimulations, e.g. hormones, growth factors, 
cytokines and stress signals, are relayed from the cell surface through an elegant 
cascade of phosphorylation events leading to the cell nucleus, where a diverse array of 
intracellular responses occur [295]. In general, ERK1/2 are preferentially activated in 
response to growth factors that act through receptor tyrosine kinases, e.g. epidermal 
growth factor (EGF), fibroblast growth factor (FGF) and PDGF, whereas the 
JNK1/2/3 and p38 (α/β/γ/δ) MAPKs are more responsive to pro-inflammatory 
cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β or stress 
stimuli ranging from osmotic shock to ionizing radiation [289, 290, 295]. 
 
Consistent with their critical roles in key cellular activities, including cell proliferation, 
differentiation, survival and apoptosis [296], the MAPK signaling pathway has also 
been implicated in the migration of various cell types [297]. Accumulating data 
suggest that MAPKs are essential in regulating the dynamics of focal adhesion and 
the reorganization of microtubules and filamentous actin that is required for cell 
morphogenesis and migration [297]. ERK1/2 is the most extensively studied 
subfamily of MAPKs and has been implicated in the migration of a wide range of cell 
types. Numerous studies have reported the ERK pathway inhibitors PD98059 and 
U0126 suppress cell migration in response to ECM, such as fibronectin, vitronectin 
and collagen [298, 299], growth factors, such as EGF, FGF, PDGF and VEGF [300-
303], and other stimuli, such as fetal bovine serum and urokinase-type plasminogen 
activator (uPA) [304, 305]. 
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Figure 8. Schematic of the three mammalian mitogen-activated protein kinase 
(MAPK) signaling pathways. Extracellular stimuli activate the MAPK pathways through 
mechanisms mediated by GTPases, including RAS, RAC, CDC42 (cell-division cycle 42) and RHO 
(RAS homologue). Once MAPKKKs (MAPK kinase kinases), such as RAF, MEKK (MAPK/ERK 
kinase kinase) and TAK (TGFβ-activated kinase), are activated, they phosphorylate MAPKKs (MAPK 
kinases) on two serine residues. MAPKKs in turn phosphorylate the MAPKs ERK (extracellular-
signal-regulated kinase), JNK (JUN N-terminal kinase) and p38 on both threonine and tyrosine 
residues, which results in the catalytic activation of these MAPKs. Activated MAPKs can translocate to 
the nucleus to phosphorylate a number of transcription factors, such as ternary complex factor (TCF) 
family members and components in the activator protein 1 (AP1) complexes, including JUN and 
activating transcription factor 2 (ATF2), thereby altering gene transcription. TCF forms a complex with 
serum response factor (SRF) to regulate Fos induction. AP1 is involved in the transcription of a wide 
variety of genes. Adapted from [306]. 
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3.8 Summary 
Although small bone defects may heal through the body’s normal reparative process, 
large skeletal deficits overwhelm this system and may fail to reach a satisfied 
structural and functional recovery, despite the use of conventional reconstructive 
approaches. With the recent advanced research in regenerative medicine and tissue 
engineering, cell-based therapy has emerged as one of the most promising approaches 
for tissue repair and regeneration. Cell-cell interaction between host and donor cells is 
believed to play a critical role in enhancing the healing process after in vivo cell 
transplantation. However, little is known about how donor cells lead to tissue repair 
and regeneration after transplantation or how they interact with the host cells in vivo. 
In addition, a comprehensive understanding of the host response to the transplanted 
donor cells is crucial for developing novel clinical strategies based on the active host 
cell contribution to the regeneration of damaged tissues. The recruitment process of 
endogenous cells may be facilitated by external stimuli, such as the manipulation of 
donor cells and the application of homing factors, which may offer new therapeutic 
options to harness the host’s innate capacity for the repair and regeneration of bone 
defects. Migration of MSCs is controlled by complicated signal networks. 
Understanding the molecular mechanisms of MSC migration will help to develop 
strategies to facilitate the tissue forming capacity of cell delivery therapy and to 
optimize cell-based bone tissue engineering.  
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ABSTRACT 
Background: The interaction between host and donor cells is believed to play an 
important role in bone tissue engineering. However, it is still unclear how donor cells 
behave and interact with host cells in vivo. The purpose of this study was to track the 
interactions between transplanted osteogenic cells and donor cells during osteogenesis.  
 
Methods: An in vitro migration assay was carried out to investigate the ability of 
osteogenically differentiated human mesenchymal stromal cells (O-hMSCs) to recruit 
undifferentiated mesenchymal stromal cell (MSCs). At the in vivo level, O-hMSCs 
were implanted subcutaneously or into skull defects in severe combined 
immunodeficient (SCID) mice. New bone formation was observed by µCT and 
histological procedures. In situ hybridisation (ISH) against human Alu sequences was 
performed to distinguish donor cells from host cells.  
 
Results: The in vitro migration assay revealed an increased migration potential of 
MSCs by co-culturing with O-hMSCs. In agreement with the results of in vitro studies, 
ISH against human Alu sequences showed that host mouse MSCs migrated in large 
numbers into the transplantation site in response to O-hMSCs, suggesting that donor 
cell characteristics may help to recruit the host MSCs for transplantation success. 
Interestingly, host cells recruited by O-hMSCs were the major cell populations in 
newly formed bone tissues, indicating that O-hMSCs can trigger and initiate 
osteogenesis when transplanted in orthotopic sites. 
 
Conclusions: The observations from this study demonstrated that in vitro induced O-
hMSCs were able to attract host MSCs in vivo and were involved in the osteogenesis 
together with host cells, which may be of importance for bone tissue engineering 
applications. 
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INTRODUCTION 
Rapid expansion of knowledge regarding progenitor cell-based tissue engineering 
offers new insights into the treatment of various kinds of diseases [24], especially 
those related to bone defects as a result of tumour, infection, trauma, biochemical 
disorders, and abnormal skeletal development [307]. Cell transplantation is one of the 
most promising strategies used to enhance the tissue-healing process, as it introduces 
functioning cells directly into affected areas [308, 309]. The concept of cell-based 
therapy involves cell isolation from autologous, allogenic, or xenogenic sources, cell 
proliferation and differentiation in vitro, and application in vivo [23, 310, 311]. 
Recently, this concept has been tested in large bone defect healing in several studies 
[39, 312].  
 
Cell-cell interactions between host and donor cells are believed to play an important 
role in enhancing the healing process after in vivo cell transplantation [313]. In cell 
therapy for bone defect healing, the delivery of osteogenic cells into the defect area is 
often considered to be of direct help to the new bone formation [314]. Due to the 
reduced multipotency compared with progenitor cells, osteoblasts may be more 
committed to form new bone tissue [64]. A study on the rabbit mandible showed that 
transplantation of osteoblast-like cells has the potential to promote maturity of the 
distracted callus [315]. Another study reported that transplantation of bone marrow 
stromal cells contributed to new bone formation in vivo [316]. However, until now, 
cell therapy for bone tissue engineering has focused on determining a source of 
exogenous cells with osteogenic capacity, without paying attention to the possibility 
that the recipient itself might provide the cell elements necessary for tissue repair. 
Little evidence shows how and to what extent the transplanted donor osteogenic cells 
behave and interact with host mesenchymal stromal cells (MSCs) during the new 
bone formation process [317]. The purpose of this study was to investigate how 
transplanted osteogenically differentiated human MSCs (O-hMSCs) were involved in 
osteogenic processes and how they interact with host MSCs after transplantation.  
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MATERIALS AND METHODS 
Cell culture 
Human bone marrow was sourced from patients (n=5, three females and two males) 
in the Department of Orthopaedics at Prince Charles Hospital, with informed consent 
and ethics approval from the Ethics Committee of Queensland University of 
Technology. The average age of the patients involved in this study was 69.6 ± 3.7 
(range 65-75) years. The hMSCs for this study were isolated by density gradient 
centrifugation over Lymphoprep™ (Axis-Shield PoC AS, Oslo, Norway) according to 
the manufacturer’s protocol [318, 319]. The cells were then seeded in culture flasks in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco®, Life Technologies Pty Ltd., 
Australia) containing 10% (v/v) fetal bovine serum (FBS; In Vitro Technologies, 
Australia) and 1% (v/v) penicillin/streptomycin (P/S; Gibco®, Life Technologies Pty 
Ltd., Australia). Following 3 days incubation in a humidified atmosphere of 5% CO2 
at 37ºC, the non-adherent cells were washed away leaving behind the adherent cell 
population that was growing in clusters. Upon reaching 70-80% confluence, the 
attached hMSCs were subcultured after treatment with 0.25% trypsin (Gibco®, Life 
Technologies Pty Ltd., Australia) and 1mM EDTA (Gibco®, Life Technologies Pty 
Ltd., Australia). In vitro osteogenic differentiation of hMSCs was performed in 
osteogenic medium (DMEM supplemented with 10% FBS, 1% P/S, 10 mM β-
glycerophosphate, 50 µM ascorbic acid and 100 nM dexamethasone; Sigma Aldrich, 
Australia) for 2 weeks. 
 
Characterisation of hMSCs 
To confirm the phenotype of hMSCs obtained through in vitro culture, flow 
cytometric analysis against the cell surface markers CD34, CD45, CD73, CD90 and 
CD105 (BD Biosciences, North Ryde, NSW, Australia; Clontech, Palo Alto, CA, 
USA) was performed [320]. Briefly, after incubation with primary antibodies against 
the aforementioned cell markers and repeated washing with 3% PBS/bovine serum 
albumin (BSA), hMSCs were resuspended and incubated with secondary antibody 
(phycoerythrin-conjugated goat anti-mouse immunoglobulin G; Jackson 
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ImmunoResearch Laboratories, West Grove, PA, USA), then resuspended in 3% 
PBS/BSA and read through in a flow cytometry machine (Becton-Dickinson, Cowley, 
Oxford, UK). In the negative control, the primary antibody was omitted and replaced 
by a mouse isotype IgG. 
 
In vitro migration assay 
hMSCs (1×10
4
) were seeded on polyethylene terephthalate (PET) track-etched 
membrane transwell inserts (10 mm effective diameter of membrand with 8 µm pore 
size; Becton-Dickinson Labware, Franklin Lakes, NJ, USA). After 24 h of cell 
attachment, the transwell inserts were assembled onto the 12-well companion plates 
cultured with 1×10
4
 hMSCs, which were subjected to osteogenic differentiation (O-
hMSCs) or retained in undifferentiated condition (hMSCs) for 2 weeks prior to the 
migration assay. All co-cultures were performed in serum-free medium to rule out the 
effect of serum in complete medium on the migration of hMSCs. Cell migration was 
allowed to proceed for 8 h. Cells that had migrated to the other side of the insert 
membrane were fixed, and then stained with crystal violet. Images were taken with an 
inverted microscope (Eclipse TS100, Nikon Australia Pty Ltd.). The migration was 
quantified by counting the number of cells that migrated through the pores in six 
randomly selected fields on each transwell insert membrane, and values from three 
independent experiments, with triplicate samples in each experiment, were averaged 
and showed as mean ± SD. 
 
In vitro osteogenic differentiation of hMSCs on collagen scaffolds 
Collagen scaffolds were fabricated from a 1mm thick bovine type I collagen sheet 
(Medtronic Australia Pty Ltd, North Ryde, NSW, Australia), using a hole puncher 5 
mm across and sterilized with 75% ethanol, followed by three rinses of PBS prior to 
cell seeding. For the in vitro osteogenic differentiation, 6×10
4 
hMSCs were first 
seeded onto the collagen membrane and cultured in osteogenic medium for 2 weeks. 
Collagen with no cells and collagen with undifferentiated hMSCs were used as 
controls. 
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In vivo implantation of osteogenically differentiated hMSCs 
Nine 5 week-old male severe combined immunodeficient (SCID) mice (Animal 
Resources Centre, Canning Vale, WA, Australia) were used for the skull defect model 
[78, 321], and another three SCID mice were used for subcutaneous cell implantation. 
For the skull defect implantation, an incision was made longitudinally along the 
centre line of the shaved skull skin. A 2.5mm diameter defect was then made through 
the skull, using a dental burr. The defect was treated as follows with three mice in 
each group: i.e. defects filled with collagen scaffold, collagen carrying 
undifferentiated hMSCs, or collagen carrying O-hMSCs. For the subcutaneous cell 
implantation, three longitudinal incisions were made in each animal along the central 
line of the shaved dorsum, approximately 1 cm apart. Each individual pocket received 
one scaffold from each group, using a complete randomized design for cell-free 
collagen scaffolds, collagen scaffolds carrying hMSCs, or collagen scaffolds carrying 
O-hMSCs. The SCID mice were sacrificed 2 weeks after subcutaneous implantation 
and 4 weeks after the skull defect implantation. 
 
Micro-computed tomography (μCT) assessment 
All the samples harvested were fixed in 4% paraformaldehyde overnight at room 
temperature and then washed in PBS. Cross-sectional scans parallel to the cell-
seeding surface of the implants were performed in a µCT scanner (µCT40, Scanco 
Medical AG, Brüttisellen, Switzerland) at a resolution of 12 µm and three-
dimensional (3D) images of the implants were reconstructed. The calcified area inside 
the implant on each scanned slice was circled out and the volume of calcification 
within the implants was measured using the inbuilt scanner software package and 
recorded for statistical analysis. 
 
Histology and immunohistochemistry (IHC) 
All harvested subcutaneous samples were embedded in paraffin blocks for sectioning, 
while the skull defect samples were first decalcified in 10% EDTA solution for 4 
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weeks and then embedded in paraffin. 5 µm serial sections were cut from the 
embedded samples, using a microtome (Leica Microsystems GmbH, Wetzlar, 
Germany). Only sections close to the centre of the samples were used for the staining.  
 
For haematoxylin and eosin (H&E) staining, tissue slices were dewaxed in xylene and 
rehydrated in descending concentrations of ethanol (100%, 90% and 70%), then 
stained with Mayer’s haematoxylin (HD Scientific Supplies Pty Ltd., NSW, Australia) 
for 2 min before rinsing with tap water for 5 min. The slides were dehydrated in 
ascending concentration of ethanol (70%, 90% and 100%) then stained with eosin 
(HD Scientific Supplies Pty Ltd., NSW, Australia) for 15 s, cleared with xylene and 
mounted with DPX mounting medium (Fronine, Laboratory Supplies, NSW, 
Australia). 
 
IHC staining was performed for the assessment of new bone formation in the skull 
defects. In brief, sections were blocked with 10% swine serum for 1 h, then incubated 
with primary alkaline phosphatase antibody (ALP; 1:400, anti-human; Sigma-Aldrich, 
Australia) overnight at 4°C. The sections were washed free of primary antibody and 
incubated with biotinylated secondary antibody (Dako, CA, USA) for 15 min, 
followed by incubation with horseradish peroxidise (HRP)-conjugated streptavidin-
biotin complex (Dako, CA, USA) for 15 min. Antibody complexes were visualized by 
the addition of diaminobenzidine (DAB) for 3 min. The sections were then lightly 
counterstained with haematoxylin and mounted with mounting medium. 
 
von Kossa staining 
In order to observe the calcification in subcutaneous implants, samples were subjected 
to 5% silver nitrate (Sigma-Aldrich, Australia) and exposed to light for 30 min. The 
sections were then washed in distilled water and dehydrated in ethanol before being 
mounted with cover slips and mounting medium. 
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In situ hybridisation (ISH) 
To trace the donor cells (i.e O-hMSCs) in skull defect sites and subcutaneous implants, 
human Alu probe was obtained from PanPath (Budel, the Netherlands). Briefly, 
hybridisation of the Alu probe was carried out for 16 h at 37°C in a humidified 
chamber after denaturation at 95°C for 5 min, followed by post-hybridisation washing 
procedure. 3-Amino-9-ethylcarbazole (AEC) was then applied to visualize the 
hybridisation. The sections were then counterstained with haematoxylin, and mounted 
with Crystal Mount
TM
 aqueous mounting medium (Sigma-Aldrich, Australia).  
 
The localisation of transplanted human cells identified by the Alu probe in both 
subcutaneous and skull defect scaffolds was observed, recorded and analysed. The 
lining cells around the initial bone were counted as osteoblasts and those trapped in 
the bone matrix and isolated in lacunae were counted as osteocytes. Three sections 
from each group were included and the cell percentage of both donor human cells and 
host mouse cells in three randomly selected areas on each section within the implant, 
newly-formed bone tissues and bone marrows adjacent to the implants or from the 
femur was calculated and recorded for further analysis.  
 
Statistical analysis 
Non-parametric Kruskal-Wallis test was performed to distinguish the differences 
among all the groups in the in vitro migration assay and the µCT quantified data 
analysis. The differences of cell percentage between donor and host cells inside 
samples were subjected to Wilcoxon test. Significant difference was considered at 
p<0.05.  
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RESULTS 
hMSCs characterisation and in vitro osteogenic differentiation 
To verify the cells derived from the human bone marrow are MSCs, a panel of 
antibodies against stem cell markers was chosen to evaluate the phenotypes of the 
hMSCs used in the present study. Flow cytometry against CD34, CD45, CD73, CD90, 
and CD105 revealed that the in vitro expanded hMSCs were negative for 
haematopoietic cell surface markers of CD34 and CD45, while positive for selected 
mesenchymal cell surface markers of CD73, CD90 and CD105 (Figure 9A). The 
hMSCs derived from the bone marrow showed typical fibroblastic morphology 
(Figure 9B). von Kossa staining showed calcium precipitation by hMSCs after in 
vitro osteogenic differentiation, confirming the mineralization potential of hMSCs 
derived from bone marrow (Figure 9C).  
 
Figure 9. hMSCs characterisation and in vitro osteogenic differentiation. (A) Flow 
cytometric analysis of cell surface antigen expression in hMSCs showed negative expression of 
haematopoietic cell surface markers (CD34 and CD45) and positive expression of mesenchymal cell 
surface markers (CD73, CD90 and CD105). (B) Microscopic observation of undifferentiated hMSCs 
showed typical fibroblastic morphology. (C) von Kossa staining showed the mineralization potential of 
hMSCs after osteogenic differentiation. 
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In vitro migration assay 
The effect of O-hMSC on the migration of hMSCs was assessed using a transwell 
device containing a cell culture insert with 8 µm pores. After 8 h of incubation, the 
number of hMSCs which migrated through the transwell membrane increased 
significantly in the co-culture with O-hMSCs (Figure 10A, D, G) compared with the 
serum-free medium (Figure 2A, B, E) and the co-culture with undifferentiated hMSCs 
(Figure 10A, C, F) (p<0.05).  
 
Figure 10. In vitro migration assay. (A) Comparison of the number of hMSCs that migrated to 
the other side of the insert membrane among different groups. SF, serum-free medium; hMSC, 
undifferentiated hMSCs were seeded in the companion plate; O-hMSC, osteogenically differentiated 
hMSCs were seeded in the companion plate (*p<0.05). (B)-(D) Schematics representation of co-culture 
groups. (E)-(G) Images of hMSCs that migrated to the other side of the insert membrane: (E) Serum-
free medium; (F) hMSCs were seeded in the companion plate; and (G) O-hMSCs were seeded in the 
companion plate.  
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Osteogenesis in subcutaneous and skull defect implants 
H&E staining on ectopic implants showed no histological signs of new bone 
formation (Figure 11I-K). However, µCT and von Kossa staining showed 
mineralization along collagen fibres in the scaffolds carrying O-hMSCs (Figure 11C, 
D, L). There was no mineralization in the scaffolds carrying undifferentiated hMSCs 
or in the cell-free scaffolds (Figure 11A, B, D). 
 
H&E staining revealed significant new bone formation, showing a trabecular bone-
like structure within the implants carrying O-hMSCs in the skull defect areas (Figure 
11O). µCT scanning and 3D reconstruction revealed that a substantial amount of 
mineralization was found in the implants carrying O-hMSCs, showing the greatest 
volume of the calcified areas (Figure 11G, H). However, there was almost no new 
bone formation within the cell-free or undifferentiated hMSCs-carrying implants in 
the skull defect areas (Figure 11E, F, H, M, N). The newly formed bone in the O-
hMSCs implants was further confirmed by IHC staining against ALP (Figure 11P).  
 
Cell migration in ectopic sites 
In the subcutaneous implants, ISH against human Alu sequences revealed that host 
mouse cells (Alu-negative) migrated into the centre of the implants, gathered together 
and were then surrounded by donor O-hMSCs. This showed a close relationship 
between the transplanted human cells and the host mouse cells in the osteogenic 
process (Figure 12D). On the other hand, in the cell-free or undifferentiated hMSCs-
loaded scaffolds (Figure 12B, C), the host mouse cells distributed sparsely in the 
transplanted scaffolds. A higher host:donor cell ratio was found inside the scaffolds 
when O-hMSCs were implanted subcutaneously (Figure 12A; p<0.05). 
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Figure 11. Osteogenesis in subcutaneous and skull defect implants. (A)-(C) 3D images of 
subcutaneous implants with scaffold only, scaffold+hMSCs or scaffold+O-hMSCs. (D) Quantification 
of the bone volume of the calcified areas within the subcutaneous implants (*p<0.05). (E)-(G) 3D 
images of skull defect treated with scaffold only, scaffold+hMSCs or scaffold+O-hMSCs. (H) 
Quantification of bone volume of the calcified areas within the skull defect implants (*p<0.05). (I)-(K) 
H&E staining of the subcutaneous implants showed no new bone formation in all three groups. (L) von 
Kossa staining revealed calcification within the subcutaneous implants carrying O-hMSCs. H&E 
staining of skull defect filled with scaffold alone (M) and scaffold+hMSCs (N), showing no new bone 
formation. (O) H&E staining of skull defect filled with scaffold+O-hMSCs showing new bone 
formation. (P) ALP staining revealed active osteoblasts in the new bone tissues in skull defect treated 
with scaffold +O-hMSCs. 
 
 
 
49 | P a g e  
 
 
 
Figure 12. Distribution of donor human cells and host mouse cells in the 
subcutaneous implants revealed by ISH. (A) Quantification and comparison of host:donor cell 
ratio between the hMSCs and O-hMSCs groups hMSC, undifferentiated hMSCs; O-hMSC, 
osteogenically differentiated hMSCs (*p<0.05). (B) Implants with collagen scaffold only. (C) Implants 
with hMSCs showing both the donor (red, arrow) and host cells (blue, arrowhead). (D) Implants with 
O-hMSCs showing both the donor (red, arrow) and host cells (blue, arrow head). 
 
Cell migration in orthotopic sites 
In the skull defect areas, ISH against human Alu sequences revealed that more than 
60% of total cells in the observed areas were host mouse cells within the O-hMSCs 
implants (Figure 13A; p<0.01). In newly formed bone tissues, O-hMSCs were found 
to turn into both osteoblasts and osteocytes (Figure 13D-F). However, the number of 
human-originated osteoblasts and osteocytes were significantly less than the cells 
from the host, indicating more host cells were involved in the newly formed bone 
tissues (Figure 13B-F; p<0.05). 
 
 
 
50 | P a g e  
 
Alu-positive cells in the newly formed bone marrow 
In the bone marrow of the newly formed bone within the implants carrying O-hMSCs, 
Alu-positive cells were identified coexisting with host marrow cells and occupied 
about 30% of total bone marrow cells (Figure 13H). Some Alu-positive cells were 
round in shape and mixed with Alu-negative host cells in the newly formed bone 
marrow, while others were found attached to the endosteal bone surfaces (Figure 
13G). In the bone marrow close to the defect, no Alu-positive cells were found 
(Figure 13I).  
 
To investigate whether transplanted donor cells migrated into the circulation system, 
femur samples from the same animal after cell transplantation were collected and 
processed. No Alu-positive cells were found in bone marrow collected from the femur 
samples, indicating that transplanted O-hMSCs were only involved in local 
osteogenesis (Figure 13J). 
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Figure 13. Distribution of O-hMSCs and host mouse cells in the skull defect implants 
and bone marrows, revealed by ISH. (A)-(C) Quantification and comparison of cell percentage 
between donor and host cells (O-hMSC: osteogenically differentiated hMSCs): (A) General cell 
percentage; (B) Cell percentage as osteoblasts; (C) Cell percentage as osteocytes (*p<0.05, **p<0.01). 
(D)-(F) Skull defect implants showed both the donor (red) and host cells (blue); arrows, donor cells-
derived osteoblasts on new bone surface; arrowhead, donor cells-derived osteocytes. (G) Bone marrow 
in skull defect showing both donor human cells (red) and host mouse cells (blue); arrow, marrow cell-
like transplanted donor cells; arrowhead, endosteal cell-like transplanted donor cells. (H) 
Quantification and comparison of cell percentage between donor O-hMSCs and host mouse cells in 
bone marrow (*p<0.05). (I) Bone marrow adjacent to the skull defect. (J) Bone marrow in the femur of 
the mouse with cell-transplanted skull defect. 
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DISCUSSION 
Cell therapies have tremendous potential to treat a wide array of diseases, and the 
major strategy of cell transplantation is via scaffolds, which are intended to serve as 
templates for tissue formation [322]. However, integration of templated tissues with 
host tissues remains a significant challenge. Since MSCs were first isolated from bone 
marrow [323], they have been considered to be among the most important stem cell 
sources for cell therapy, due to their multilineage differentiation capacity [116, 324, 
325]. Although the osteogenic differentiation potential of MSCs has been well 
characterised in many in vitro and in vivo studies [110, 326-328], no study has been 
conducted so far to clarify how the donor cells interact with the host cells in the 
osteogenic process. 
 
In the present study, the in vivo behaviour of O-hMSCs was investigated using the 
ISH technique against human Alu sequences in both subcutaneous (ectopic) and skull 
defect (orthotopic) osteogenesis. The results showed that O-hMSCs played a 
significant role in host cell recruitment in both ectopic and orthotopic sites. The cell 
distribution and the ratio of donor:host cells were significantly different in ectopic and 
orthotopic sites.  
 
Subcutaneous transplantation of O-hMSCs revealed that the host cells migrated into 
the centre of O-hMSCs and exhibited almost a 50:50 donor:host cell ratio. This 
phenomenon may indicate that ectopic osteogenesis of transplanted O-hMSCs needs 
the involvement of a certain amount of host cells to generate an optimal local 
microenvironment for initial calcification. The host cells formed cell clusters or 
nodules among the transplanted cells, indicating close cell-cell communication 
between host and donor cells.  
 
In the skull defect areas, a substantial of newly formed bone tissue was found in 
implants carrying O-hMSCs. It is very interesting to find that these transplanted O-
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hMSCs were involved in the new bone formation and differentiated to both 
osteoblasts and osteocytes at a similar donor:host cell ratio. Our finding of a large 
number of recipient cells at the defect sites confirmed cell migration into the defect. 
More host cells than donor cells differentiated into osteoblasts and osteocytes in skull 
defect areas. This is different from the subcutaneous implant, which showed a nearly 
equivalent number between the host and donor cells. This difference might be 
attributed to the different local environment (ectopic and orthotopic) and different 
osteogenic process (calcification and new bone formation). The smaller number of O-
hMSCs compared with host cells as osteoblasts and osteocytes in skull defect areas 
may indicate that transplanted donor cells played a more important role in initiating 
osteogenesis, rather than in maintaining the bone formation process. Different 
proliferation rates between the human and mouse cells, postoperative complications 
present at the defect sites, and other factors, such as immunological reactions, may 
also tip the balance in favour of the recipient cells. 
 
Another interesting aspect of tracking the transplanted donor cells is to investigate the 
role of donor cells in the reconstitution of bone marrow in the newly formed bone, 
and whether they could enter the blood flow and circulate into the bone marrow cell 
compartment. In this study, only in the bone marrow cavities in the skull defects were 
the donor cells found. This means that at the 4 week time point, the donor cells could 
recruit host haematopoietic cells to form bone marrow in newly formed bone. 
However, donor cells did not travel to the far end of body extremities. In the new 
bone marrow, transplanted cells took up a lower cell percentage than the host marrow 
cells. Considering the similarly low percentage of donor O-hMSCs as osteoblasts and 
osteocytes in newly formed bone tissues, in vivo osteogenesis seems to require more 
involvement of host cells than donor cells. In the bone marrow, some transplanted 
cells presented the round shape of host marrow cells, but some were attached to the 
endosteal bone cavity surface. This phenomenon suggests some transplanted cells 
could become endosteal cells.  
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The reason why O-hMSCs recruited more MSCs compared to undifferentiated 
hMSCs is not clear. It is possible that cytokines released by O-hMSCs may have 
stimulated MSCs to travel toward O-hMSCs. A recent study demonstrated that SDF-
1, a member in the chemokine family, is important for the migration of MSCs to bone 
marrow [164]. Many studies have shown that during tissue repair, local SDF-1 
expression is upregulated and acts as a signal to recruit the CXCR4 (SDF-1 ligand) 
expressing cells from circulation and/or bone marrow. Apart from chemokines, other 
molecular factors, such as fibroblast growth factor (bFGF) [329], matrix 
metalloproteinases (MMPs) [330], and TLR ligation [331] were known to increase the 
migratory homing activity of MSCs to the damaged tissue. It is possible that one or 
more of the factors described above, or other factors unknown, are induced by O-
hMSCs, giving rise to a positive feedback of the host MSCs, which in turn trigger the 
bone formation. 
 
This study demonstrated that in both ectopic and orthotopic sites, transplanted O-
hMSCs could recruit host cells to initiate osteogenesis involving the formation of 
osteoblasts, osteocytes, and bone marrow components. The ratio of donor:host cells 
inside the transplants were significantly dependent on the local environment and 
directly correlated with osteogenesis. This new finding provides the groundwork for 
future studies about the interaction between transplanted donor cells and host cells in 
bone defect healing. 
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ABSTRACT 
Background: Cell-cell interaction is believed to play important roles in the cell-based 
therapy for bone defect healing. However, it is still unclear what factors are involved 
in the interaction between donor cells and host cells during the bone healing process. 
The purpose of this study was to investigate the potential effect of vascular 
endothelial growth factor (VEGF) on the expression pattern of CXCL12/CXCR4 with 
respect to the interactions between undifferentiated and osteogenically differentiated 
mesenchymal stromal cells (MSCs and OMSCs) in vitro and in vivo.  
 
Methods: Indirect co-culture models were applied to study the effect of VEGF 
derived from OMSCs on the motility, the cell morphology and the CXCL12/CXCR4 
expression of MSCs in vitro. The role of VEGF in the regulation of the host cell 
recruitment was monitored by the application of neutralizing VEGF antibody in vivo, 
after OMSC implantation into the skull defects in SCID mice.  
 
Results: Our data showed that VEGF secretion increased dramatically in MSCs after 
osteogenic differentiation in vitro and the secretion of VEGF promoted the motility of 
MSCs with elongated actin filament and enhanced the expression of 
CXCL12/CXCR4. In vivo findings revealed remarkable new bone formation within 
the defects implanted with OMSCs. Furthermore, blocking VEGF with neutralizing 
antibody resulted in significant decrease of MSCs recruitment and new bone 
formation. 
 
Conclusions: The observations from this study demonstrate that VEGF secreted by in 
vitro induced OMSCs plays a pivotal role in MSC recruitment possibly via the 
activation of the CXCL12/CXCR4 axis during osteogenesis. 
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INTRODUCTION 
Bone defect remains one of the most prevalent clinical problems even though various 
strategies to stimulate bone healing have been explored [78, 332-335]. Due to 
morbidity issues in donor sites and the limited availability of autografts, allograft 
transplantation has become an attractive alternative treatment option. However, the 
clinical results are limited and sometimes associated with poor clinical predictability 
and severe adverse reactions [336]. In order to overcome these limitations, it is of 
great interest to develop novel biological strategies, which require elucidation of the 
molecular signals responsible for successful bone regeneration. 
 
Cell-based therapy, such as mesenchymal stromal cell (MSC) transplantation, is a 
promising strategy for the treatment of bone defects. MSCs are attractive candidates 
for cell-based bone regeneration [337], because of their capacity to differentiate into 
osteogenic lineage following in vitro expansion and osteogenic induction. The 
development, remodelling and repair of bone are controlled by the proliferation, 
differentiation, migration and apoptosis of various cell types, including osteoblasts, 
osteoclasts and haematopoietic cells [338]. Although a lot of studies have focused on 
the ability of implanted cells to differentiate within the defect sites, more recent 
research suggests other important factors may be involved in the bone tissue 
regeneration, such as the regulation of direct or indirect cell-cell interactions [339, 
340], as well as the release of soluble factors [341]. However, the paracrine factors 
and molecular mechanisms that contribute to the interaction between host cells and 
donor cells during osteogenesis are poorly understood. 
 
Recent studies have shown that cellular movement and relocalisation are essential for 
many fundamental physiologic properties, including angiogenesis, chemotaxis, and 
osteogenesis [342, 343]. Osteogenesis and angiogenesis are two closely correlated 
processes during bone formation and regeneration [344]. Vascular endothelial growth 
factor (VEGF) is highly expressed in vascularised tissues and can promote endothelial 
cell proliferation, differentiation and migration from pre-existing vasculatures. As the 
best characterised angiogenic mediator, VEGF is believed to play a crucial role in 
skeletal development by enhancement of angiogenesis [345, 346]. On the other hand, 
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a key feature regulating cell movement is chemotaxis, which induces migration via 
signaling molecules termed chemokines [347, 348]. Chemokines are a large family of 
small, basic polypeptides that have mainly been characterised as chemoattractants. 
They navigate trafficking and localisation for various cell type in tissue compartments 
[349]. The interaction between chemokine (C-X-C motif) ligand 12 (CXCL12) and its 
receptor CXCR4 is believed to be the most important contributor to MSC homing to 
areas of tissue damage and is involved in tissue regeneration [350-354]. However, 
there is little information to be found regarding the potential effect of VEGF on the 
expression pattern of CXCL12/CXCR4 with respect to the recruitment of MSCs 
during new bone formation. We therefore investigated whether VEGF secretion by 
osteogenically differentiated MSCs (OMSCs) was associated with CXCL12/CXCR4 
expression alterations, which may lead to the migration and recruitment of MSCs in 
the osteogenic process. 
 
MATERIALS AND METHODS 
Cell culture 
Human bone marrow samples were obtained from patients (n=3) undergoing elective 
knee replacement surgery in the Department of Orthopaedics at Prince Charles 
Hospital with informed consent from each patient and ethics approval from the Ethics 
Committee of Queensland University of Technology. Bone marrow was sourced from 
the femoral canal. After draining of synovial fluid, a femoral drill hole was made 
through the distal femur and an intramedullary rod was passed into the femoral canal 
allowing marrow aspirates to be collected with a syringe. Bone marrow-derived 
MSCs for this study were isolated by density gradient centrifugation over 
Lymphoprep (Axis-shield PoC AS, Oslo, Norway) according to the manufacturer’s 
protocol. The cells were then seeded in culture flasks in low glucose Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco®, Life Technologies Pty Ltd., Australia) 
containing 10% (v/v) fetal bovine serum (FBS; In Vitro Technologies, Australia) and 
1% (v/v) penicillin/streptomycin (P/S; Gibco®, Life Technologies Pty Ltd., Australia) 
at 37°C, 5% CO2. The medium was changed twice weekly to wash out all non-
adherent cells. Adherent bone marrow-derived MSCs were then passaged once grown 
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to 70%-80% confluence. Cell characterisation for MSCs has been carried out in our 
previous study [318, 355]. 
 
Osteogenic differentiation of bone marrow-derived MSCs  
Isolated MSCs were subjected to a 2-week osteogenic differentiation in osteogenic 
medium (DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10 mM 
β-glycerophosphate, 50 µM ascorbic acid and 100 nM dexamethasone; Sigma Aldrich, 
Australia) for further experiments. Medium was changed twice weekly. 
 
Alizarin Red S staining 
In order to identify mineralization nodules, Alizarin Red S staining was performed on 
day 14 after MSCs and OMSCs had grown to a confluent monolayer in a 6-well plate. 
The medium was removed and the cells were washed with PBS and fixed with 100% 
methanol for 10 min at room temperature. After rinsing with distilled water, the cells 
were stained in a solution of 1% Alizarin Red S (Sigma-Aldrich, Australia) at pH 4.1 
for 20 min and the excessive solution was then washed away. The samples were air 
dried and photos were taken under a microscope (Eclipse TS100, Nikon Australia Pty 
Ltd.). 
 
Preparation of conditioned medium (CM) 
CM was obtained from 1×10
7 
MSCs (CM
MSC
) or OMSCs (CM
OMSC
). The cells were 
washed twice with PBS, and then incubated with 10 mL of serum-free DMEM at 
37
o
C for 48 h. The CM was then collected, subjected to centrifugation at speed of 
1000 g for 5 min at 4
o
C and filtration through a 0.2 µm low protein binding filter 
(Millipore Corporation, Billerica, MA, USA) to remove cell debris. The supernatants 
were stored at -80
o
C for subsequent experiments.  
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Enzyme-linked immunosorbent assay  
The concentration of VEGF in CM
MSC
 and CM
OMSC
 was tested using ELISA assay kit 
for VEGF (R&D Systems Inc., Australia) according to the manufacture’s instruction. 
Briefly, all the samples and standards were incubated in the assigned wells of the 96-
well plate for 2 h at room temperature. After three washings, 200 µL VEGF conjugate 
was added into each well and incubated for 2 h at room temperature. After washing, 
the amount of conjugate bound to each well was determined by the addition of 200 µL 
substrate solution. The reaction was quenched by adding 50 µL stop solution per well 
and measured immediately at 450 nm with a microplate reader (SpectraMax, Plus 384, 
Molecular Devices, Inc., USA). The test was performed in triplicate, and the VEGF 
levels were determined using the generated standard curve. All the results were 
expressed as the amount (pg) of VEGF in per µL CM.  
 
Indirect co-culture 
The CM from MSCs or OMSCs was mixed with fresh culture medium in a ratio of 
1:1 before applying to MSCs with or without the addition of 20 ng/mL VEGF 
neutralizing antibody (R&D Systems Inc., Australia). The medium was changed every 
three days. MSCs were harvested for RNA and protein on day 6 for subsequent 
experiments. 
 
In vitro migration assay 
MSCs (5×10
4
) were seeded on transwell inserts with 8 µm pore size (Becton-
Dickinson Labware, Franklin Lakes, NJ, USA). After 24 h of cell attachment, the 
transwell inserts were assembled onto the 6-well companion plates cultured with 
5×10
4
 MSCs, which were subjected to osteogenic differentiation (OMSCs) or retained 
in undifferentiated condition (MSCs) for 2 weeks prior to the migration assay. All co-
cultures were performed in serum-free medium with or without the addition of 20 
ng/mL VEGF neutralizing antibody. Cell migration was allowed to proceed for 8 h. 
Cells that had migrated to the other side of the insert membrane were fixed, and then 
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stained with crystal violet. Images were taken with an inverted microscope (Eclipse 
TS100, Nikon Australia Pty Ltd.). The migration was quantified by counting the 
number of cells that migrated through the pores in six randomly selected fields on 
each transwell insert membrane, and values from three independent experiments were 
averaged and shown as mean ± SD. 
 
xCELLigence system monitored cell migration  
The real-time migration tendency of MSCs in response to CM
MSC
 and CM
OMSC
 was 
further monitored using the CIM-Plate 16 and xCELLigence system RTCA DP 
Instrument (Roche Products Pty Ltd., Australia). The CIM-Plate 16 is a 16-well 
modified Boyden chamber composed of an upper chamber (UC) and a lower chamber 
(LC). The UC is sealed at the bottom by a microporous polyethylene terepthalate 
(PET) membrane. These micropores allow the physical translocation of cells from the 
upper part of the UC to the bottom side of the membrane, which is covered with 
interdigitated gold microelectrode sensors. As migrated cell attach and spread on the 
electrode sensors, it leads to an increase in electrical impedance [356]. The LC 
contains 16 wells, each of which serves as a reservoir for a chemoattractant solution. 
In the present study, 100 µL of cell suspension (4×10
4
 cells) were added to each well 
of the UC after serum starvation for 4 h. The UC was then placed on the LC of the 
CIM-Plate 16 containing 160 µL CM
MSC
 and CM
OMSC 
respectively, with or without 
VEGF neutralizing antibody as an attractant. Cell migration was monitored over a 
period of up to 12 h. The generated impedance signal was displayed as a 
dimensionless parameter termed cell index, which was directly proportional to the 
total area of the cell-culture well. 
 
VEGF stimulation of MSCs 
In order to further investigate the effect of VEGF on the expression pattern of 
CXCL12/CXCR4, cell culture medium supplemented with 20, 40, 80 ng VEGF 
(R&D Systems Inc., Australia) per mL was applied to the MSCs. The medium was 
replenished every three days through a 6-day culture period, after which the cells were 
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harvested and subjected to real time quantitative PCR (RT-qPCR) and Western 
blotting analysis.  
 
Fluorescent staining for morphological changes 
2×10
3
 MSCs were seeded on each coverslip (ProSciTech, QLD, Australia) placed in a 
24-well plate. After overnight culture in serum-free medium, CM
MSC
, and CM
OMSC
 
with or without VEGF neutralizing antibody, the MSCs were fixed with 4% 
paraformaldehyde (PFA) for 30 min. Fixed cells were permeabilized with 0.1% Triton 
X-100 in PBS for 5 min and washed twice with 0.1% BSA/PBS. The nuclei were 
stained with 0.1 µg/mL DAPI (Life Technologies Pty Ltd., Australia) for 30 min, and 
the actin filaments were labelled with rhodamine phalloidin (Life Technologies Pty 
Ltd., Australia). After washing, the coverslips were mounted with ProLong® Gold 
(Life Technologies Pty Ltd., Australia) and secured to glass slides with three spots of 
nail varnish. Morphological characteristics were identified under a fluorescent 
microscope. The shapes of the fluorescent signals induced by the conditioned medium 
were analysed using the integrated morphometry shape factor analysis of MetaMorph 
image analysis software version 7.1.2 (Universal Imaging, Downingtown, PA, USA). 
In the present study, we used a standard shape factor defined by (area/perimeter
2
) × 
4π for quantitative analysis of cell shape [357]. This algorithm assigns a value from 0 
to 1, describing the shape of a perfect circle attains a value of 1 and a line is assigned 
as 0. 
 
RNA extraction, cDNA synthesis, and real time quantitative-PCR (RT-qPCR) 
The mRNA expression of alkaline phosphatase (ALP), osteopontin (OPN) and 
osteocalcin (OCN) and VEGF was measured in MSCs and OMSCs to detect the 
difference before and after osteogenic differentiation. The expression of CXCL12 and 
CXCR4 in MSCs was also measured after co-culture with different CM and VEGF 
treatment. Total RNA was extracted from the cells with TRIzol Reagent (Ambion
®
, 
Life Technologies Pty Ltd., Australia). Complementary DNA was synthesized from 1 
μg of total RNA using DyNAmo™ cDNA Synthesis Kit (Finnzymes, Genesearch Pty 
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Ltd., Australia) following the manufacturer’s protocol. The RT-qPCR primers (Table 
1) were designed based on cDNA sequences from the NCBI Sequence database and 
the primer specificity was confirmed by BLASTN searches. RT-qPCR was performed 
on an ABI Prism 7300 Sequence Detection System (Applied Biosystems, Australia) 
using SYBR
®
 Green detection reagent (Applied Biosystems, Australia). In brief, 
cDNA samples (2.5 μL of 1:10 diluted template for total volume of 25 μL per reaction) 
were analysed for the genes of interest and for the GAPDH house keeping gene. The 
cycling conditions were set as follows: 2 min at 95°C for activation followed by 45 
cycles of denaturation at 95°C for 5 sec, annealing at 60°C for 10 sec, and extension 
at 72°C for 15 sec. The specificity of amplification was verified by a single peak in 
the melting curve. All reactions were run in triplicate for three independent 
experiments. Dissociation curve analysis was performed to validate the absence of 
primer dimmers and nonspecific PCR products. The mean cycle threshold (Ct) value 
of each target gene was normalized against Ct value of GAPDH and the relative 
expression calculated using the following formula: 2
-(normalized average Cts)
 ×10
4
 [358]. 
 
Table 1. Primer sequences for the gene observed in this study 
Gene 
name 
Forward sequences Reverse sequences 
ALP 5’TCAGAAGCTCAACACCAACG 5’TTGTACGTCTTGGAGAGGG
C 
OCN 5’CACCGAGACACCATGAG 5’TGGAGAGGAGCAGAACTG 
OPN 5’CCAAGTAAGTCCAACGAAAG 5’GGTGATGTCCTCGTCTGTA 
VEGF 5’GCTGTCTTGGGTGCATTGG 5’GCAGCCTGGGACCACTTG 
CXCL12 5’GCTACAGATGCCCATGCCGA
TTC 
5’CCTGAATCCACTTTAGCTTC
GGGTC 
CXCR4 5’CCAGAAGAAACTGAGAAGC
ATGACGG  
5’CCAGACGCCAACATAGACC
ACC 
GAPDH 5’ TCAGCAATGCCTCCTGCAC 5’ TCTGGGTGGCAGTGATGGC 
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Protein extraction and Western blotting 
Total protein was harvested by lysing the cells in a lysis buffer containing 20 mM 
HEPES (pH 7.4), 10% glycerol, 1% Triton X-100, 2mM EGTA and a protease 
inhibitor cocktail (Roche Products Pty. Ltd., Dee Why, NSW, Australia). The protein 
concentration was determined by the BCA Protein Assay Kit (Thermo Fisher 
Scientific, VIC, Australia). 20 µg of protein from each sample was separated by 8% 
SDS-PAGE gels. The protein was then transferred onto a nitrocellulose membrane 
(Pall Corporation, East Hills, NY, USA). After blocking for 1 h with blocking buffer 
(1×Tris-buffered saline with 5% skim milk and 0.01% Tween-20), the membranes 
were probed with primary antibodies against VEGF (1:1000 rabbit anti-human), 
CXCL12 (1:1000, rabbit anti-human), CXCR4 (1:1000, rabbit anti-human) and α-
Tubulin (1:5000, rabbit anti-human) overnight at 4°C. The primary antibodies were 
all obtained from Abcam (Sapphire Bioscience Pty. Ltd., Waterloo, NSW, Australia). 
The membranes were washed three times for 20 min each in TBS containing 0.01% 
Tween-20, and then incubated with horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit secondary antibody (Abcam; Sapphire Bioscience Pty. Ltd., Waterloo, 
NSW, Australia) at 1:2000 dilution for 1 h at room temperature. Targeted proteins 
were visualized using the SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Fisher Scientific, Australia) and exposed on x-ray film (Fujifilm, Australia). 
Bands intensities were quantified by scanning densitometry and analysed using 
ImageJ software [359].  
 
Animal study and drug administration 
Collagen scaffolds were fabricated from a 1mm-thick bovine Type-I collagen sheet 
(Medtronic Australia Pty Ltd, North Ryde, NSW, Australia) using a hole puncher and 
sterilized by soaking in 75% ethanol, followed by three rinses of PBS prior to cell 
seeding. For the in vitro osteogenic differentiation, 6×10
4
 MSCs were firstly seeded 
onto collagen membrane and cultured in osteogenic medium for 2 weeks.  
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Twelve 5-week old male SCID mice (Animal Resources Centre, Canning Vale, WA, 
Australia) were used for the skull defect model [78, 321] and subcutaneous cell 
implantation, respectively. For the skull defect implantation, an incision was made 
longitudinally along the centre line of the shaved skull skin after anaesthesia. A 3 mm 
defect was then made through the skull using a dental bur. The collagen membrane 
carrying OMSCs were inserted into the defects of each mice. For the subcutaneous 
cell implantation, a longitudinal incision was made in each animal along the central 
line of the shaved dorsal. Each individual pocket received one collagen scaffold 
carrying OMSCs. Six mice were assigned to experimental group using a complete 
randomized design, which received local injection of 20 ng VEGF neutralizing 
antibody in 100 uL PBS for two weeks. The other six mice in the control group 
received 100 uL of PBS. All of the SCID mice were sacrificed after four weeks and 
the implants were retrieved. 
 
Micro-computed tomography (μCT) assessment 
All the samples harvested were fixed in 4% PFA overnight at room temperature and 
then washed in PBS. Cross-sectional scans parallel to the cell seeding surface of the 
implants were performed in a micro-CT scanner (µCT40, SCANCO Medical AG, 
Brüttisellen, Switzerland) at a resolution of 12 µm and three-dimensional (3D) images 
of the implants were reconstructed. The calcified area inside the implant on each 
scanned slice was circled out and the volume of calcification within the implants was 
measured using the inbuilt scanner software package and recorded for statistical 
analysis. 
 
Histology and immunohistochemistry (IHC)  
All harvested subcutaneous samples were embedded in paraffin block for slicing, 
whereas the skull defect samples were firstly decalcified in 10% EDTA solution for 
four weeks and then embedded in paraffin. 5 µm serial slices were cut from the 
embedded samples using a microtome (Leica Microsystems GmbH, Wetzlar, 
Germany). Only slices close to the centre of the samples were used for the staining.  
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In order to observe the calcification in subcutaneous implants, sample was subjected 
to von Kossa with H&E staining. The slices were dewaxed in xylene and then 
hydrated in 100%, 90%, and 70% ethanol for 3 min each. After the application of 5% 
silver nitrate solution (Sigma-Aldrich, Australia), the slices were exposed to light for 
1 h. After rinsing in distilled water, 5% sodium thiosulphate was added to the slices 
for 5 min. The slices were then washed in tap water, placed in Harris’s haematoxylin 
(Sigma-Aldrich, Australia) for 2 min then rinsed in tap water before dipping 3 times 
in acid ethanol. After dehydration, eosin (HD Scientific Supplies Pty Ltd., NSW, 
Australia) was applied to the slices for 15 sec. The slices were then rinsed in 100% 
ethanol twice and cleared in xylene before being mounted with cover slips. 
 
IHC staining was performed for assessment of new bone formation in the skull 
defects. Briefly, endogenous peroxidase activity was quenched by incubating with 3% 
H2O2. After washing with PBS, all the sections were blocked with 10% swine serum 
for 1 h. Sections were then incubated with optimal dilution of primary antibodies 
against ALP (1:400, anti-human, Sigma-Aldrich, Australia) overnight at 4°C. Sections 
were washed free of primary antibodies and then incubated with a biotinylated 
secondary antibody (Dako, CA, USA) for 15 min, followed by 15 min incubation with 
HRP-conjugated streptavidin-biotin complex (Dako, CA, USA). Antibody complexes 
were visualised after the addition of a buffered diaminobenzidine (DAB) for 3 min.  
 
In situ hybridisation (ISH)  
To verify the origin of cells in skull defect sites, ISH was performed using a human 
specific digoxigenin (DIG)-labelled oligonucleotide probe (PanPath, Budel, the 
Netherlands), which detects Alu repeat sequences found in human chromosomes. 
Briefly, tissue sections were dewaxed and rehydrated through a descending ethanol 
series with RNase-free reagents, and then treated with proteinase K for 10 min. One 
drop of the ready-to-use Alu probe solution was added onto each section and the 
slices were covered with a coverslip. After heating at 95
o
C for 5 min, the slices were 
incubated at 37°C in a humidified chamber overnight followed by post-hybridisation 
67 | P a g e  
 
washing procedure. 3-Amino-9-ethylcarbazole (AEC) was then applied to visualise 
the bound probe. After rinsing in distilled water, the sections were lightly 
counterstained with haematoxylin, then mounted with Crystal Mount
TM
 aqueous 
mounting medium (Sigma-Aldrich, Australia).  
 
For ISH and IHC double staining, after the donor human cells were detected using the 
Alu DNA probe, which was visualised with NiCl2+DAB (staining colour is black), 
the first primary antibody (VEGF) was applied and visualised with DAB (staining 
colour is brown). The host mouse cells were then stained with Nuclear Fast Red 
(Sigma-Aldrich, Australia). After rinsing with tap water, the sections were dehydrated 
with ascending concentrations of ethanol, cleared with xylene and mounted with a 
cover slip. 
 
Statistical analysis 
Statistical evaluation was performed using SPSS software (SPSS, Sigma Stat, Erkrath, 
Germany). Differences between two groups were assessed by Student t-test. 
Differences in the treatment outcomes from different conditions were assessed by 
analysis of variance (ANOVA) with Bonferroni post-hoc test. Values of p<0.05 were 
considered statistically significant. 
  
68 | P a g e  
 
RESULTS 
OMSCs express high level of VEGF 
Histology images showed a close interaction between donor human OMSCs and host 
mouse cells in the newly formed bone tissues from the skull defect model (Figure 14). 
Furthermore, the ISH together with IHC staining revealed that the donor OMSCs 
strongly expressed VEGF, giving a clue that VEGF secreted by donor OMSCs may 
play a role in the host cell recruitment (Figure 14A and B). 
 
 
Figure 14. Histological evaluation of a skull defect model after a 4-week implantation 
of OMSCs. (A) Representative image showing host mouse cells were recruited to the bone defect 
area and involved in the new bone formation with donor human cells (20×). (B) 40× magnification of 
the selected area, showing the VEGF secretion from OMSCs, as well as the close interaction between 
donor cells and host cells. Host mouse cells were stained with Nuclear Fast Red (pink colour, dashed 
arrow pointed); Donor human cells were stained with NiCl2+DAB (black colour, arrow pointed); 
VEGF was stained with DAB (brown colour, arrowhead pointed). NB: newly formed bone. 
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Alizarin Red S staining was performed and the result showed that the mineralization 
in MSCs was significantly enhanced after osteogenic differentiation (Figure 15A). 
The mRNA level of ALP, OPN and OCN also showed significant increase in OMSCs 
(Figure 15B, p<0.05). VEGF gene expression of OMSCs increased remarkably 
(Figure 15C, p<0.05). ELISA result showed that VEGF secretion was significantly 
elevated in MSCs after exposure to osteogenic medium (Figure 15D, p<0.01). 
Western blotting analysis further confirmed the elevated VEGF protein level (Figure 
15E, p<0.05). 
 
 
Figure 15. VEGF secretion from OMSCs. (A) Alizarin Red S staining showed the 
mineralization in MSCs was significantly enhanced after cultured in osteogenic medium for 2 weeks. 
(B) mRNA transcripts of ALP, OCN and OPN, showed a significant increase in OMSCs (*p<0.05). (C) 
VEGF gene expression of MSCs increased remarkably after osteogenic differentiation (*p<0.05). (D) 
ELISA result showed that VEGF secretion significantly elevated in OMSCs (**p<0.01). (E) and (F) 
Western blotting analysis showed greater VEGF expression in OMSCs in the protein level, as indicated 
by the significantly higher band density (*p<0.05). 
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VEGF secreted by OMSCs induced the migration of MSCs 
After 8 h incubation, the migration of MSCs through the transwell membrane was 
significantly enhanced in the co-culture with OMSCs compared with the serum-free 
medium or the co-culture with MSCs (Figure 16C, D and I, p<0.01). However, the 
number of migrated MSCs dropped dramatically when the OMSCs were treated with 
VEGF neutralizing antibody (Figure 16D and J, p<0.01). The increased motility of 
MSCs toward OMSCs was further confirmed using the xCELLigence system. The 
cell index of MSCs in CM
OMSC
 was elevated throughout the experimental period, but 
dropped down to the level as that in the CM
MSC
 when VEGF neutralizing antibody 
was applied (Figure 16K, p<0.05). The data demonstrated that VEGF secreted by 
OMSCs serves as a chemoattractant to MSCs.  
 
Morphological changes of MSCs cultured in CM
OMSC
 
As described above, enhanced migration of MSCs was observed in the indirect co-
culture with OMSCs, indicating a more mobile MSC phenotype was induced. We 
then further investigated the effect of CM
OMSC 
on the morphological and cytoskeletal 
changes in MSCs. Figure 17 shows MSCs cultured in CM
OMSC
 underwent remarkable 
morphological alterations compared with those cultured in CM
MSC
 over the same 
period of time. Actin filaments organized along the length of the cell, making the 
general appearance of cell as an elongated rod shape (Figure 17B). However, the 
application of VEGF neutralizing antibody in CM
OMSC 
led to a reversed effect (Figure 
17C). Cell shape factor changed from around 0.5 to 0.1, indicating a transformation 
from a more regular and round shape to an irregular and elongated cell shape when 
MSCs were grown in the CM
OMSC 
instead
 
of CM
MSC
. Additionally, when VEGF 
neutralizing antibody was added into the CM
OMSC
, the cells tended to regain a higher 
shape factor, indicative of the importance of VEGF in maintaining the migratory 
phenotype (Figure 17D, p<0.05).  
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Figure 16. VEGF neutralizing antibody interfered with the migration of MSCs 
towards OMSCs. (A)-(D) and (I) The migration capacity of MSCs towards OMSCs was 
significantly superior to the control groups (SF, serum-free medium; MSC, undifferentiated 
mesenchymal stromal cells; OMSC, osteogenically differentiated mesenchymal stromal cells; 
**p<0.01). (A)-(D) and (J) The number of migrated MSCs decreased significantly with the addition of 
20 ng/mL VEGF neutralizing antibody (*p<0.05). (K) The increased motility of MSCs toward OMSCs 
was further confirmed by the xCELLigence system (*p<0.05).  
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Figure 17. Morphological and cytoskeletal changes in MSCs cultured in CM
OMSC 
with or without the addition of VEGF neutralizing antibody. (A)-(C) MSCs cultured in 
CMOMSC showed elongated actin filaments. The application of VEGF neutralizing antibody in CMOMSC 
led to a reversed effect. (D) The shape factor of MSCs cultured in CMOMSC was significantly lower than 
that in CMMSC and CMOMSC + Abvegf (*p<0.05).  
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CM
OMSC
 increased the CXCL12/CXCR4 expression of MSCs 
We then further tested the effect of VEGF secreted by OMSCs on the expression 
pattern of CXCL12/CXCR4, which is believed to be the most important axis that 
contributes to MSCs homing to areas of tissue damage. When MSCs were cultured in 
CM
OMSC
, the CXCL12/CXCR4 mRNA expression showed a significant elevation 
(Figure 18A and B, p<0.05) compared to those cultured in CM
MSC
. Furthermore, the 
expression of CXCL12/CXCR4 decreased when VEGF neutralizing antibody was 
added into CM
OMSC
 (Figure 18A and B, p<0.05). The change of CXCL12/CXCR4 
expression was further confirmed by the Western blotting results (Figure 18C-E, 
p<0.05).  
 
 
Figure 18. CM
OMSC
 increased the CXCL12/CXCR4 expression of MSCs. (A) and (B) 
mRNA levels of CXCL12 and CXCR4 were significantly elevated in MSCs cultured in CMOMSC 
(*p<0.05). However, the expression of CXCL12/CXCR4 decreased when VEGF neutralizing antibody 
was applied (*p<0.05). (C)-(E) The elevated expression of CXCL12/CXCR4 was further confirmed by 
the Western blotting analysis on the protein level, as indicated by the significantly higher band density 
(*p<0.05). CM
MSC
, conditioned medium derived from undifferentiated mesenchymal stromal cells; 
CMOMSC, conditioned medium derived from osteogenically differentiated mesenchymal stromal cells; 
Abvegf, VEGF neutralizing antibody. 
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CXCL12/CXCR4 expression in MSCs was stimulated by VEGF 
The effect of VEGF on the expression of CXCL12/CXCR4 in MSCs was further 
investigated by culturing the MSCs in medium supplemented with increasing 
concentration of VEGF. The results showed that the CXCL12/CXCR4 gene 
expression in MSCs enhanced significantly when stimulated by VEGF in a dose 
dependant manner (Figure 19A and B, p<0.05). Western blotting analysis showed a 
similar trend on the protein level (Figure 19C-E, p<0.05). 
 
Figure 19. CXCL12/CXCR4 expression of MSCs stimulated by VEGF. (A) and (B) 
mRNA levels of CXCL12 and CXCR4 in MSCs treated with different dosage of VEGF, showing a 
steady increase in a dose dependent manner (*p<0.05). (C)-(E) The elevated expression of 
CXCL12/CXCR4 in MSCs stimulated with increasing dosage of VEGF was further confirmed by the 
Western blotting analysis on the protein level, as indicated by the significantly higher band density 
(*p<0.05).  
75 | P a g e  
 
Inhibition of VEGF abrogated the effect of OMSCs on the recruitment of host cells  
To determine whether VEGF secreted by OMSCs plays a role in host cell recruitment 
in vivo, donor cells were implanted into skull defects of SCID mice with or without 
the local administration of VEGF neutralizing antibody. The von Kossa with H&E 
staining revealed the mineralization found in the subcutaneous implants carrying 
OMSCs was suppressed when the VEGF neutralizing antibody was applied (Figure 
20A and B). For the skull defect samples, µCT scanning and 3D reconstruction 
confirmed that VEGF neutralizing antibody significantly inhibited the bone healing 
induced by the implantation of the OMSCs. (Figure 20E and F). IHC staining against 
ALP revealed less new bone tissues in the skull defects after the local application of 
VEGF neutralizing antibody (Figure 20C and D). The results suggested that VEGF 
was involved in the accelerated bone healing induced by OMSC implantation. ISH 
against human Alu sequences revealed that host mouse cells (Alu negative) were 
recruited to the skull defect area and actively involved in the bone regeneration 
process together with the donor human OMSCs (Figure 20G). On the contrary, fewer 
host cells were found in the implants when VEGF was neutralized (Figure 20H). 
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Figure 20. Blocking VEGF with neutralizing antibody resulted in a significant 
decrease of MSC recruitment and new bone formation. (A) von Kossa with H&E staining 
showed mineralization in the subcutaneous implants carrying OMSCs. (B) von Kossa with H&E 
staining detected no mineralization when the VEGF neutralizing antibody was applied. (C) 
Immunohistochemical staining against ALP revealed newly formed bone in skull defect implanted with 
collagen scaffold carrying OMSCs. (D) Less new bone formation was detected in the skull defects after 
the local application of VEGF neutralizing antibody. (E) and (F) 3D images of skull defects implanted 
with collagen scaffold carrying OMSC, with or without the application of VEGF neutralizing antibody. 
(G) ISH staining revealed that host mouse cells (stained in purple) were recruited to the skull defect 
area and involved in the bone regeneration together with the donor human OMSCs (stained in red). (H) 
Fewer host cells were recruited to the implants when VEGF was neutralized. 
77 | P a g e  
 
DISCUSSION 
Cell implantation is currently regarded as an important and promising regime for 
repairing and restoring the biological functions of bone defects [307, 308]. Bone 
marrow-derived MSCs are promising candidates for such cell-based therapy, due to 
their immune tolerance, self-renewal capacity and ease of use [360-362]. Chemotactic 
migration of host mesenchymal progenitor cells (MPCs) from bone marrow or other 
tissues have been identified as a crucial event during various physiological and 
pathological processes [351, 353, 354]. Increasing evidence indicates that MSCs 
communicate with other cells in vivo and appear to “home” to areas of defect and 
injury in response to cellular signals. However, even though the therapeutic potential 
of MSCs is an area of great excitement and promise, the factors that trigger MSCs’ 
response and the underlying mechanisms that guide the host MSCs migrate to the 
bone defect sites are still poorly understood. In this study we have demonstrated that 
VEGF secreted by OMSCs led to the altered expression pattern of CXCL12/CXCR4 
in MSCs, and we have also provided some insights into the communication between 
host cells and donor cells during osteogenesis. 
 
MSCs secrete numerous cytokines including VEGF, bFGF, IGF-1 and HGF [363]. 
Among all these, VEGF is the key regulator in a cascade of molecular and cellular 
events that ultimately lead to the development of the vascular system [364]. VEGF is 
not only a critical mediator in physiological angiogenesis, but also a vital factor in 
skeletal growth [365]. Previous studies suggested that VEGF plays an important role 
in MSCs migration [366-368], as well as in the recruitment and proliferation of 
endothelial cells (ECs) [369]. The data from our study showed that the VEGF 
secretion increased dramatically in bone marrow-derived MSCs after osteogenic 
differentiation in vitro. Similar results have been reported previously that VEGF is 
expressed in osteoblast-like cells in a differentiation-dependent manner, indicating 
that VEGF plays a positive role in the regulation of osteoblast activity [199]. A recent 
study has also demonstrated that Osterix (Osx), an essential osteoblast-specific 
transcription factor required for osteoblast differentiation, directly targets VEGF 
expression [201], suggesting a close link between osteogenesis and angiogenesis. The 
enhanced secretion of VEGF from OMSCs was further confirmed by the ISH and 
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IHC staining, which showed a strong expression of VEGF in OMSCs correlated with 
greater recruitment of host MSCs. 
 
We then demonstrated the positive effect of VEGF on the motility of MSCs in vitro 
using transwell migration assay and real-time xCELLigence system. The results 
suggested the secreted factors derived from OMSCs were a potent chemoattractant for 
MSCs. The enhanced motility of MSCs was correlated with the changes in actin 
organization and distribution from azimuthal symmetry around the cell rim to 
concentration at a particular region [370]. In addition to morphological changes, 
MSCs underwent specific alterations in gene expression patterns in response to the 
exterior stimuli. Exposure to CM
OMSC 
enhanced migration of MSCs and this was 
accompanied by an increased expression pattern of CXCL12/CXCR4. In agreement 
with the gene expression profile, CXCL12/CXCR4 protein levels also increased in 
MSCs upon exposure to CM
OMSC
. However, the addition of VEGF neutralizing 
antibody abrogated the effect of OMSCs on the actin filament arrangement as well as 
the CXCL12/CXCR4 expression of MSCs. We further confirmed a dose-dependent 
chemoattractive effect of VEGF on MSCs. VEGF stimulation remarkably increased 
the expression of CXCL12/CXCR4, which is the best known axis that contributes to 
cell migration [352]. Additionally, the expression of CXCL12/CXCR4 in MSCs was 
down regulated when VEGF neutralizing antibody was applied, suggesting the 
secretion of VEGF from OMSCs played a crucial role in inducing the MSCs 
recruitment. 
 
The interaction between donor cells and host cells is an emerging area of research, 
and it is important to understand the mechanisms that govern this interaction. Our data 
has shown that there was differential regulation of CXCL12/CXCR4 in MSCs 
exposed to different microenvironments and that these changes influenced chemotaxis, 
an important function of MSCs. Based on the previous finding, our in vivo study 
further confirmed that OMSCs played a significant role in the host cells recruitment. 
It is very interesting to find that the transplanted OMSCs were involved in the new 
bone formation. Furthermore, the function of OMSCs in host cell recruitment was 
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supported by the elevated secretion of VEGF, which then led to the markedly 
increased expression of CXCL12/CXCR4 and changes of morphology in host MSCs 
(Figure 21). CXCL12 may signal through its receptor, CXCR4, and function in an 
autocrine manner to support chemotaxis of host cells towards the transplanted donor 
cells in the bone defect sites. The newly formed blood vessels, donor cell- and host 
cell-derived osteoblasts may work together to restore the damaged bone tissue. 
Further studies are needed to elucidate the full repertoire of CXCL12/CXCR4 
signaling in MSCs and to identify other pathways that are critical to the 
microenvironment-specific MSC biology. This will be crucial to the understanding of 
clinically important processes, such as cell transplantation, bone marrow engraftment 
and wound healing. 
 
 
Figure 21. Schematic of the proposed mechanism by which donor OMSCs initiate a 
paracrine signaling cascade that results in altered phenotype and enhanced motility of 
host MSCs in a skull defect model. The interaction between OMSCs and MSCs is centrally 
regulated by VEGF secreted by OMSCs, and involves the participation of the CXCL12/CXCR4 axis, 
which may accelerate the host cell recruitment process. 
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CONCLUSION 
We demonstrated the VEGF secreted by OMSCs plays a significant role in the 
expression pattern of CXCL12/CXCR4 of undifferentiated bone marrow-derived 
MSCs. The involvement of CXCL12/CXCR4 in the VEGF-mediated host cell 
recruitment towards skull defect was confirmed for the first time. The present study 
offers insights into the donor/host cell interaction and is of clinical significance for the 
application of cell-based therapy for bone repair and regeneration. 
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ABSTRACT 
Background: Although it has been shown that mesenchymal stromal cells (MSCs) 
are attracted to vascular endothelial growth factor (VEGF) secreted by osteogenically 
differentiated MSCs (OMSCs) in our previous study, it is still not known that how 
VEGF signals through MSCs which are expected to have low levels of VEGF 
receptors (VEGFRs) and what downstream pathways are involved in the recruitment 
of MSCs.  
 
Methods: MSCs were stimulated with different concentrations of VEGF, conditioned 
medium derived from MSCs (CM
MSC
) or OMSCs (CM
OMSC
) to establish the receptors’ 
activation profile. The role of platelet-derived growth factor receptors (PDGFRs) was 
further investigated using phospho-receptor tyrosine kinase (RTK) array, Western 
blotting analysis and in vitro migration assay. The involvement of the PI3K/Akt 
signaling pathway in OMSCs-induced MSC migration was monitored by relevant 
phosphorylated antibodies and inhibitors. 
 
Results: We found that VEGF secreted by OMSCs was capable of inducing migration 
of MSCs which are VEGFR deficient, and this induction was mediated through a 
molecular crosstalk of PDGFRs and the PI3K/Akt signaling kinase. The VEGF-
induced MSC migration paralleled with the enhanced expression of PDGFRs and the 
activation of the PI3K/Akt kinase. Blocking of PDGFRs activity impaired VEGF-
induced MSC migration as well as PI3K/Akt kinase activation. Moreover, a PI3K/Akt 
specific inhibitor, LY294002, resulted in the suppression of VEGF-induced MSC 
migration and dephosphorylation of downstream effectors of the PI3K/Akt signaling 
pathway, including Akt, mTOR, p70
S6K
 and PAK1, further supporting the role of the 
PI3K/Akt pathway in the MSC recruitment. 
 
Conclusions: The present study established a mechanistic link among VEGF, 
PDGFRs and PI3K/Akt in the regulation of MSC recruitment that eventually may be 
beneficial to the bone repair and regeneration. 
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INTRODUCTION 
The molecular interactions between donor and host cells are indispensable in the 
process of host mesenchymal stromal cells (MSCs) recruitment for tissue repair and 
regeneration. Guidance of cell migration depends critically on subcellularly localised 
perception and transduction of various signals. As has been widely reported, vascular 
endothelial growth factor (VEGF) proved to be chemoattractive for primary human 
osteoblasts [202, 203]. This provides the first evidence that VEGF may also be 
involved in local recruitment of osteoprogenitor cells in the course of endochondral 
bone formation or remodeling. VEGF exerts its effects on vascular cells by binding to 
three structurally related VEGF receptor (VEGFR) tyrosine kinases, VEGFR-1, 
VEGFR-2 and VEGFR-3, each forms homodimers on ligand binding [206]. VEGF 
and platelet-derived growth factor (PDGF) are closely related members, as evidenced 
by sequence analysis which predicts that VEGF and PDGF evolved from a common 
ancestor [207]. VEGFRs and PDGF receptors (PDGFRs) are also structurally related, 
characterised by extracellular immunoglobulin-like domains with an intracellular 
tyrosine kinase domain interrupted by a non-catalytic region [371]. Bone marrow-
derived MSCs, which can differentiate into vascular cells, may be recruited by VEGF 
during the process of angiogenesis and osteogenesis. However, several studies have 
reported that there is limited expression of VEGFR in MSCs [200, 372], leading to the 
speculation that VEGF may signal through PDGFRs and regulate the migration of 
MSCs [210]. 
 
Our previous study (REPORT TWO) has demonstrated that VEGF secreted from 
osteogenically differentiated mesenchymal stromal cells (OMSCs) played a 
significant role in the recruitment of host cells by regulating the expression pattern of 
CXCL12/CXCR4, an important axis for cell migration. The present study aimed to 
identify the downstream signaling pathways associated with the interaction between 
OMSCs and MSCs. Recent studies have reported that binding of CXCL12 to CXCR4 
may lead to stimulation of signaling cascade that involves activation of multiple 
targets, including Erk1/2, p38 and Akt [273-276]. Akt, also known as protein kinase B 
(PKB), is one of the best characterised targets of phosphoinositide 3-kinases (PI3K) 
signaling pathway, which regulates cell survival, cytoskeletal rearrangements and cell 
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invasion [252, 253]. Accumulating data suggest that major downstream effectors of 
the PI3K/Akt signaling pathway, mTOR, p70 S6 kinase (p70
S6K
) and p21-activated 
kinase 1 (PAK1), are associated with changes in actin cytoskeleton organization, cell 
shape and adhesion dynamics, and play critical roles in cell motility regulation [281, 
282, 285-287]. 
 
Here in the present study, we found that OMSCs stimulated the migration of MSCs by 
activating PDGFRs. Furthermore, our findings demonstrated VEGF/PDGFR mediated 
the activation of the PI3K/Akt signaling cascade, which led to the phosphorylation of 
mTOR, p70
S6K
 and PAK1, and was significantly associated with the cell migration 
induced by OMSCs. 
 
MATERIALS AND METHODS 
Cells and Cell culture 
Human bone marrow samples were collected from patients (n=3, 1 female and 2 
males) undergoing elective knee replacement surgery in the Department of 
Orthopaedics at Prince Charles Hospital, Brisbane, Queensland, Australia after 
obtaining informed consent from each donor and ethics approval from the Ethics 
Committee of Queensland University of Technology. Bone marrow-derived MSCs for 
this study were isolated by density gradient centrifugation over Lymphoprep (Axis-
shield PoC AS, Oslo, Norway) according to the manufacturer’s protocol. The cells 
were then seeded in culture flasks supplemented with low glucose Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco®, Life Technologies Pty Ltd., Australia) 
containing 10% (v/v) fetal bovine serum (FBS; In Vitro Technologies, Australia) and 
1% (v/v) penicillin/streptomycin (P/S; Gibco®, Life Technologies Pty Ltd., Australia) 
at 37°C, 5% CO2. The medium was changed twice weekly to wash out all non-
adherent cells. Adherent bone marrow-derived MSCs were then passaged once grown 
to 70%-80% confluence. Cell characterisation for MSCs has been carried out in our 
previous study [318, 355]. Human umbilical vein endothelial cells (HUVECs; 
Clonetics™, Lonza Australia Pty Ltd., Mt Waverley, VIC, Australia) were used as 
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positive control when required. HUVECs were routinely cultured in EGM™-2 
BulletKits™ (Lonza Australia Pty Ltd., Mt Waverley, VIC, Australia) composed of 
endothelial cell basal medium-2 (EBM-2) supplemented with 2% FBS, 
gentamicin/amphotericin-B, VEGF, human epidermal growth factor (hFGF)-B, 
insulin-like growth factor-1 (IGF-1), hEGF, ascorbic acid, hydrocortisone, and 
heparin, as described by the manufacturer (Lonza Australia Pty Ltd., Mt Waverley, 
VIC, Australia). 
 
Osteogenic differentiation of bone marrow-derived MSCs 
Isolated MSCs were subjected to osteogenic differentiation for 2 weeks in osteogenic 
medium (DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10 mM 
β-glycerophosphate, 50 µM ascorbic acid and 100 nM dexamethasone; Sigma Aldrich, 
Australia) for further experiments. 
 
Preparation of conditioned medium (CM) 
CM was obtained from 1×10
7 
MSCs (CM
MSC
) or OMSCs (CM
OMSC
). The cells were 
washed twice with PBS, and incubated with 10 mL of serum-free DMEM at 37
 o
C for 
48 h. The CM was then collected, subjected to centrifugation at speed of 1000 g for 5 
min at 4
o
C and filtration through a 0.2 µm low protein binding filter (Millipore 
Corporation, Billerica, MA, USA) to remove cell debris. The supernatants were stored 
at -80
o
C for subsequent experiments.  
 
Stimulation of MSCs 
In order to investigate the effect of VEGF on the expression pattern of VEGFRs and 
PDGFRs, cell culture medium supplemented with 20, 40, 80 ng VEGF (R&D 
Systems Inc., Australia) per mL was applied to HUVECs and MSCs. The cells were 
harvested and subjected to real time quantitative PCR (RT-qPCR) analysis after 24 h. 
MSCs were also stimulated with serum-free medium, CM
MSC
, CM
OMSC
 with or 
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without the supplementation of 20 ng/mL VEGF neutralizing antibody (R&D Systems 
Inc., Australia) to further investigate the expression pattern of various receptors. 
 
For the functional tests, MSCs were pre-treated with 5 µM PDGFR tyrosine kinase 
inhibitor (Merck Pty Ltd., Australia), 10 µM LY294002 (Cell Signaling Technology, 
Inc. Danvers, MA, USA) or DMSO as control 30 min prior to the stimulation of 
CM
MSC
 and CM
OMSC
. MSCs were harvested for RNA and protein at different time 
points (e.g. 15 min, 30 min and 60 min) according to subsequent experiments.  
 
In vitro migration assay using transwell chambers 
MSCs migration was monitored using 6-well transwell cell culture Boyden chambers 
with 23.1 mm effective diameter polyethylene terephthalate (PET) membrane 
containing 8 µm pores (Becton-Dickinson Labware, Franklin Lakes, NJ, USA). 5×10
4
 
MSCs were firstly seeded on to each transwell chamber for the initial attachment. 
After serum-starved overnight, the transwell chambers were assembled onto the 6-
well companion plates supplemented with CM from MSCs or OMSCs. To attenuate 
the PDGFR in MSCs, 5 µM PDGFR tyrosine kinase inhibitor was applied. Non-
specific effects of the inhibitor were ruled out by repeating the migration assay in the 
presence of an unrelated antibody against an intracellular antigen IgG. Cell migration 
was allowed to proceed for 8 h. Cells that had migrated to the other side of the 
transwell membrane were fixed, and stained with crystal violet. Images were taken 
with an inverted microscope (Eclipse TS100, Nikon Australia Pty Ltd.). The 
migration was quantified by counting the number of cells that migrated through the 
pores in six randomly selected fields on each transwell membrane, and values from 
three independent experiments, with triplicate samples in each experiment, were 
averaged and shown as mean ± SD. 
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Phospho-receptor tyrosine kinase (RTK) array 
A human phospho-receptor tyrosine kinase (RTK) array kit (R&D Systems Inc., 
Australia) was used to simultaneously detect the relative tyrosine phosphorylation 
levels of 49 different RTKs in the untreated or CM-treated MSC lysates. Each array 
contains duplicate validated controls and captures antibodies for specific RTKs. 
MSCs were serum-starved for 12 h and then stimulated with CM
MSC
 or CM
OMSC
 for 
15 min at 37°C in a humidified atmosphere with 5% CO2, then immediately placed on 
ice, washed twice with chilled PBS, and harvested using the lysis buffer that comes 
with the RTK array kit. Total protein concentration was quantitated using the BCA 
Protein Assay Kit (Thermo Fisher Scientific, VIC, Australia). RTK array analysis was 
performed according to the manufacturer’s protocol. In brief, the array membranes 
were blocked, and then incubated with 250 µg MSC lysate overnight at 4°C. After 
washing, the membranes were incubated with anti-phospho-tyrosine-HRP for 2 h at 
room temperature, then washed again, and developed with detection reagent. RTK 
spots were visualized on x-ray film (Fujifilm, Australia).  
 
RNA extraction, cDNA synthesis, and real time quantitative-PCR (RT-qPCR) 
Total RNA was extracted from the cells with TRIzol
®
 Reagent (Ambion
®
, Life 
Technologies Pty Ltd., Australia). Complementary DNA was synthesized from 1 μg 
of total RNA using DyNAmo™ cDNA Synthesis Kit (Finnzymes, Genesearch Pty 
Ltd., Australia) following the manufacturer’s protocol. The RT-qPCR primers (Table 
2) were designed based on cDNA sequences from the NCBI Sequence database and 
the primer specificity was confirmed by BLASTN searches. RT-qPCR was performed 
on an ABI Prism 7300 Sequence Detection System (Applied Biosystems, Australia) 
using SYBR
®
 Green detection reagent Applied Biosystems, Australia). In brief, 
cDNA samples (2.5 μL of 1:10 diluted template for total volume of 25 μL per reaction) 
were analysed for the genes of interest and for the GAPDH house keeping gene. All 
reactions were run in triplicate for three independent experiments. Dissociation curve 
analysis was performed to validate the absence of primer dimmers and nonspecific 
PCR products. The mean cycle threshold (Ct) value of each target gene was 
88 | P a g e  
 
normalized against Ct value of GAPDH and the relative expression calculated using 
the following formula: 2
-(normalized average Cts)
 ×10
4 
[358]. 
 
Table 2. Primer sequences for the gene observed in this study 
Gene 
name 
Forward sequences Reverse sequences 
VEGFR-1 5’CCCTTATGATGCCAGCAAGT
G 
5’CCAAAAGCCCCTCTTCCAA 
VEGFR-2 5’CAAACGCTGACATGTACGG
TCTA 
5’CCAACTGCCAATACCAGTG
GAT 
VEGFR-3 5’GTCAGGGGAGATCATCGGG
AC 
5’GGAGCTGGTGGTGAATGTG
CCC 
PDGFR-α 5’GATAGCTTCCTGAGCCACCA
C 
5’CATAGAGTGATCTCTGGAT
GTCGG 
PDGFR-β 5’GGAGACCCGGTATGTGTCA
GAGC 
5’CCAGCACTCGGACAGGGAC
ATTG 
GAPDH 5’ TCAGCAATGCCTCCTGCAC 5’TCTGGGTGGCAGTGATGGC 
 
Protein extraction and Western blotting 
Total protein was harvested by lysing the cells in a lysis buffer containing 20 mM 
HEPES (pH 7.4), 10% glycerol, 1% Triton X-100, 2mM EGTA and a 
phosphatase/protease inhibitor cocktail (Roche Products Pty. Ltd., Dee Why, NSW, 
Australia). The protein concentration was determined by the BCA Protein Assay Kit 
(Thermo Fisher Scientific, VIC, Australia). 15 µg of protein from each sample was 
separated by 8% SDS-PAGE gels, and then the separated protein was transferred to 
nitrocellulose membrane (Pall Corporation, East Hills, NY, USA). After blocking for 
1 h with Odyssey® blocking buffer (Millennium Science, Australia), the membranes 
were incubated with the primary antibodies against PDGFR-α (1:1000, rabbit anti-
human), PDGFR-β (1:1000, rabbit anti-human), Akt (1:2000, mouse anti-human), 
phospho-Akt (Ser473) (1:2000, rabbit anti-human), Erk1/2 (1:2000, mouse anti-
human), phospho-Erk1/2 (1:2000, rabbit anti-human), mTOR (1:1000, mouse anti-
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human), phospho-mTOR (1:1000, rabbit anti-human), p70
S6K
 (1:1000, rabbit anti-
human), phospho-p70
S6K
 (Thr389) (1:1000, rabbit anti-human), PAK1 (1:1000, rabbit 
anti-human), phospho-PAK1 (Ser144)/PAK2 (Ser141) (1:1000, rabbit anti-human), 
and α-Tubulin (1:4000, rabbit anti-human) overnight at 4oC. The primary antibodies 
were all obtained from Cell Signaling (Cell Signaling Technology, Inc. Danvers, MA, 
USA). The membranes were washed three times for 20 min each in TBS containing 
0.01% Tween-20, and then incubated with corresponding fluorescent secondary 
antibodies (Cell Signaling Technology, Inc. Danvers, MA, USA) at 1:2000 dilution 
for 1 h at room temperature. Targeted proteins were visualized using the Odyssey® 
infrared imaging system. Band intensities were quantified by scanning densitometry 
and analysed using ImageJ software [359].  
 
Statistical analysis 
Statistical evaluation was performed using SPSS software (SPSS Inc., Chicago, Il, 
USA). Values are expressed as mean ± standard deviation (SD). One-way analysis of 
variance followed by Student’s t-test was used to determine statistically significant 
differences between experimental and control samples. Significant difference was 
considered at p<0.05.  
 
RESULTS 
Expression profile of VEGFR and PDGFR in MSCs 
RT-qPCR analysis was performed using total RNA isolated from MSCs, with human 
umbilical vein endothelial cells (HUVECs) as positive control. Only a very low level 
of VEGFR-1, VEGFR-2, or VEGFR-3 mRNA transcripts were determined in MSCs 
compared to HUVECs, with or without the stimulation of different concentration of 
VEGF, reflecting the lack of VEGFRs in MSCs (Figure 22). On the contrary, both 
VEGFR-1 and VEGFR-2 were readily detected in HUVECs, showing a steady 
increase after exposure to VEGF (Figure 22). Interestingly, the treatment of MSCs 
with different concentration of VEGF under serum-free condition significantly 
augmented the expression of PDGFR-α and PDGFR-β in MSCs (Figure 22, p<0.05).  
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Figure 22. The expression of VEGFR and PDGFR mRNA transcripts was examined 
by RT-qPCR analysis, using HUVECs as positive control. H: HUVECs; B: bone marrow-
derived mesenchymal stromal cells; SF: serum-free medium; BCM: conditioned medium from bone 
marrow-derived MSCs; OCM: conditioned medium from osteogenically differentiated bone marrow-
derived MSCs; 20v: 20 ng/mL VEGF; 40v: 40 ng/mL VEGF; 80v: 80 ng/mL VEGF. 
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Furthermore, the co-culture with CM derived from OMSCs enhanced the expression 
of PDGFRs, but failed to reveal an increase in the levels of VEGFRs. Importantly, the 
application of 20 ng/mL VEGF neutralizing antibody impaired the PDGFRs 
expression in MSCs induced by CM
OMSC
. These data indicated that PDGFR-α and 
PDGFR-β may be the key players in VEGF dependent or CMOMSC-induced migration 
of MSCs, whereas VEGFRs, although required for VEGF-mediated endothelial cells 
(ECs) migration [373], are unlikely to be involved. 
 
CM
OMSC
-induced PDGFR-α and PDGFR-β tyrosine phosphorylation in MSCs 
Having demonstrated the enhanced expression profile of PDGFRs in MSCs after 
stimulated with CM
OMSC
, we next examined whether CM
OMSC
 could lead to PDGFR 
tyrosine autophosphorylation by using a human phospho-RTK array containing 49 
different specific RTK antibodies. RTK screening of CM
OMSC 
treated MSCs revealed 
distinct PDGFR-α and PDGFR-β tyrosine phosphorylation (Figure 23C). In 
comparison, the cell lysate from serum-free medium or CM
MSC
 treated
 
MSCs showed 
a barely detectable level of tyrosine phosphorylation (Figure 23A and B). The 
neutralization of VEGF was accompanied by a significant decrease in CM
OMSC
-
induced PDGFRs activation (Figure 23D). Interestingly, no VEGFR tyrosine 
phosphorylation was detected, further validating that the MSCs biological activity 
stimulated by CM
OMSC 
was not mediated through VEGFRs. 
 
Western blotting analysis also demonstrated that, compared to CM
MSC
,
 
CM
OMSC
 
enhanced
 
PDGFR-α and PDGFR-β expression of MSCs in protein level (Figure 24A). 
The supplementation of VEGF neutralizing antibody led to a substantial decrease of 
PDGFR expression in MSCs (Figure 24A-C, p<0.05), indicating that CM
OMSC
-
induced MSCs activity may be dependent on a PDGFR-mediated mechanism. 
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Figure 23. CM
OMSC
-induced tyrosine phosphorylation of PDGFR-α and PDGFR-β in 
MSCs. Human phospho-RTK array was used to examine RTK phosphorylation levels in MSCs lysate 
samples. RTK array analysis of (A) MSCs cultured in serum-free medium without supplementation of 
exogenous growth factor; (B) MSCs cultured in CM
MSC
; (C) MSCs stimulated with CM
OMSC
; (D) 
MSCs cultured in CMOMSC supplemented with VEGF neutralizing antibody. 
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Figure 24. The levels of protein expression of PDGFR-α and PDGFR-β in MSCs in 
response to different stimulations. (A) Western blotting evaluation of PDGFR-α and PDGFR-β 
expressions of MSCs in protein level after stimulation with CMMSC and CMOMSC with or without the 
addition of VEGF neutralizing antibody. (B) and (C) Quantitative measurement of the protein band 
density of PDGFR-α and PDGFR-β. The expressions of PDGFR-α and PDGFR-β elevated when MSCs 
were stimulated with CMOMSC. The addition of VEGF neutralizing antibody in CMOMSC led to reduced 
levels of protein expression of both PDGFR-α and PDGFR-β (*p<0.05). CMMSC, conditioned medium 
derived from undifferentiated mesenchymal stromal cells; CMOMSC, conditioned medium derived from 
osteogenically differentiated mesenchymal stromal cells; Abvegf, VEGF neutralizing antibody. 
 
Role of PDGFRs in CM
OMSC
-induced MSC migration 
To examine whether PDGFRs participate in CM
OMSC
-induced MSC migration which 
has been proven in the previous study (REPORT TWO), the activity of PDGFRs was 
blocked by treating the MSCs with PDGFR tyrosine kinase inhibitor for 8 h. In vitro 
transwell migration assay revealed that pre-treatment of PDGFR tyrosine kinase 
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inhibitor mediated inhibition of PDGFRs action, which significantly impaired 
CM
OMSC
-induced MSC migration, resulting in substantial reduction of migrated cells 
(Figure 25E, F and G, p<0.05). On the other hand, pre-treatment with either VEGFR-
1 or VEGFR-2 inhibitor did not alter CM
OMSC
-induced MSC migration (p>0.05; data 
not shown).  
 
Figure 25. The involvement of PDGFR in MSC migration induced by CM
OMSC
. (A)-(C) 
Schematics representation of in vitro migration assay settings. The bottom chambers were 
supplemented with (A) CMMSC, (B) CMOMSC and (C) CMOMSC with PDGFR tyrosine kinase inhibitor. 
(D)-(F) Representative images of MSC migration induced by (D) CMMSC, (E) CMOMSC and (F) CMOMSC 
with PDGFR tyrosine kinase inhibitor. (G) The migration capacity of MSCs was significantly 
stimulated by CMOMSC compared to CMMSC. PDGFR tyrosine kinase inhibitor was applied to attenuate 
the PDGFR bioactivity and the number of migrated MSCs decreased dramatically (*p<0.05). CMMSC, 
conditioned medium derived from undifferentiated mesenchymal stromal cells; CMOMSC, conditioned 
medium derived from osteogenically differentiated mesenchymal stromal cells; PDGFRi, PDGFR 
tyrosine kinase inhibitor. 
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Activation of the PI3K/Akt signaling is required for CM
OMSC
-induced MSC 
migration  
To determine the signaling pathways involved in the CM
OMSC
-induced MSC 
migration, we then examined the effect of PDGFR tyrosine kinase inhibitor on the 
phosphorylation of Akt and Erk1/2 in the co-culture system. MSCs were stimulated 
with CM
MSC
 and CM
OMSC 
with or without PDGFR tyrosine kinase inhibitor after 
serum-starved overnight. Following treatment, the phospho- and total levels of Akt 
and Erk1/2 were determined by Western blotting analysis. As shown in Figure 26, 
MSCs displayed a very low basal Akt phosphorylation after exposure to CM
MSC
. 
After stimulation with CM
OMSC
, a significant increase of Akt phosphorylation was 
produced, but the addition of PDGFR tyrosine kinase inhibitor resulted in a decreased 
phosphorylation. However, there was no major difference in the expression profile of 
phospho-Erk1/2. 
 
In order to further confirm the involvement of the PI3K/Akt signaling pathway in 
CM
OMSC
-induced MSC migration, MSCs were pre-treated with 10 µΜ LY294002 for 
30 min prior to their exposure to CM
OMSC
 for different time points (e.g. 15 min, 30 
min, and 60 min). As shown in Figure 27, CM
OMSC
 induced a dramatic and rapid 
elevation of phospho-Akt, reaching a maximum within 30 min of exposure followed 
by a gradual decrease observed 60 min after CM
OMSC
 stimulation. No significant 
change in total Akt expression was observed over the course of the experiment. The 
interference with the PI3K/Akt signaling by LY294002 abolished the signal 
transduction (Figure 27A and B, p<0.05). Furthermore, the inhibition of the 
PI3K/Akt signaling pathway was associated with significantly reduced migration of 
MSCs induced by CM
OMSC
 as shown in the in vitro migration assay (Figure 27C, 
p<0.05). 
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Figure 26. Akt and Erk1/2 phosphorylation status in MSCs in response to various 
stimulations. (A) Western blotting evaluation of phospho- and total levels of Akt and Erk1/2 in 
MSCs after stimulation with CMMSC and CMOMSC with or without the addition of PDGFR tyrosine 
kinase inhibitor. (B) and (C) Quantitative measurement of the protein band density of phospho-Akt and 
phospho-Erk1/2. Compared to CMMSC, CMOMSC induced a substantial phosphorylation of Akt. The pre-
treatment of PDGFR tyrosine kinase inhibitor attenuated the Akt phosphorylation induced by CMOMSC. 
No significant difference was noticed in the phosphorylation status of Erk1/2 in MSCs after different 
treatments (*p<0.05). CMMSC, conditioned medium derived from undifferentiated mesenchymal 
stromal cells; CMOMSC, conditioned medium derived from osteogenically differentiated mesenchymal 
stromal cells; PDGFRi, PDGFR tyrosine kinase inhibitor.   
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Figure 27. Activation of the PI3K/Akt signaling is required for CM
OMSC
 induced 
MSCs migration. (A) Western blotting evaluation of phospho- and total levels of Akt in CMOMSC-
stimulated MSCs at different time points with or without the pre-treatment of 10 µM LY294002. (B) 
Quantitative measurement of the protein band density of phospho-Akt. CMOMSC induced the activity of 
Akt within 30 min at highest level with gradual decrease till 60 min after stimulation. LY294002, a 
specific PI3K/Akt inhibitor, suppressed the CM
OMSC
-induced phosphorylation of Akt; (C) In vitro 
migration assay showed that CMOMSC-induced MSC migration was significantly interfered by the 
addition of LY294002 (*p<0.05). CMOMSC, conditioned medium derived from osteogenically 
differentiated mesenchymal stromal cells.  
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Activation of the PI3K/Akt signaling pathway downstream effectors 
The phosphorylation status of downstream effectors of the PI3K/Akt signaling 
pathway was evaluated by Western blotting analysis. As shown in Figure 28 A and B, 
CM
OMSC 
significantly increased the phosphorylation of mTOR, p70
S6K
, and PAK1 in 
MSCs, compared to serum-free medium and CM
MSC
. However, the phosphorylation 
status of mTOR, p70
S6K
, and PAK1 was dramatically suppressed in response to the 
pre-treatment of LY294002. 
 
Figure 28 The phosphorylation status of downstream effectors of the PI3K/Akt 
signaling pathway. (A) Western blotting evaluation of phospho- and total levels of mTOR, p70S6K 
and PAK1 in MSCs in response to various stimulations. (B) Quantitative measurement of the protein 
band density of phospho-mTOR, phospho-p70S6K, and phospho-PAK1. CMOMSC induced significantly 
increased phosphorylation of mTOR, p70S6K, and PAK1 in MSCs, compared to SF and CMMSC. 
LY294002 suppressed the CMOMSC-induced phosphorylation of mTOR, p70S6K, and PAK1 (*p<0.05). 
SF, serum-free medium; CMMSC, conditioned medium derived from undifferentiated mesenchymal 
stromal cells; CMOMSC, conditioned medium derived from osteogenically differentiated mesenchymal 
stromal cells. 
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DISCUSSION 
Targeted migration of endogenous cells to the required site is an essential aspect for 
potential therapeutic success. However, the means by which donor cells trigger the 
necessary signals required for the recruitment of host MSCs to the defect sites have 
remained a puzzling gap in knowledge. For the last decade, considerable effort has 
been directed toward identifying the signaling pathways that contribute to host cell 
migration and the regeneration of damaged tissues. Our previous studies (REPORT 
ONE and REPORT TWO) have shown that donor OMSCs attract host MSCs by 
releasing VEGF among a variety of growth factors. Only little is known, however, 
about how VEGF secreted by OMSCs signal through the downstream pathways that 
instruct the recruitment of MSCs.  
 
As a member from the VEGF/PDGF family, VEGF is the potent mitogen for 
endothelial cells (ECs). VEGF not only regulates angiogenesis/vasculogenesis and 
vascular permeability, but also induces and enhances ECs proliferation and migration 
[374]. Numerous studies have suggested that the chemoattractant activity of VEGF 
could be mediated through VEGFR-1, VEGFR-2 and VEGFR-3 [375-378]. However, 
a number of studies have reported that limited VEGFR expression was found in 
MSCs, indicating VEGF may signal through other receptors in MSCs [200, 372, 379]. 
In fact, previous reports have also demonstrated that VEGF and PDGF members are 
closely related, and VEGFRs and PDGFRs exhibit structural similarities [223, 371]. 
The PDGF ligands exert their biological activities via two distinct but structurally 
related receptors, PDGF receptor-α (PDGFR-α) and PDGFR-β. Particularly strong 
expression of PDGFR-α has been noticed in subtypes of mesenchymal progenitors in 
lung, skin and intestine, while PDGFR-β is reported to express in the mesenchyme, 
especially in vascular SMCs (vSMCs) and pericytes [222]. The present study revealed 
that although MSCs only expressed low levels of VEGFR-1, VEGFR-2 and VEGFR-
3, they did express high levels of PDGFR-α and PDGFR-β, which were activated by 
the stimulation of VEGF and CM derived from OMSCs. Furthermore, blocking the 
biological activity of PDGFR-α and PDGFR-β in MSCs by PDGFR tyrosine kinase 
inhibitor prevented MSCs migration induced by CM
OMSC
. However, the function of 
VEGFRs had no impact on MSC directional migration. Our results suggested that 
100 | P a g e  
 
functional cell surface PDGFR-α and PDGFR-β are both crucial determinants in 
mediating MSC migration induced by OMSCs.  
 
Having demonstrated that VEGF promotes mobilization of MSCs towards OMSCs 
via PDGFRs, a series of experiments were performed to identify the downstream 
signaling pathways participating in this process. The PI3K/Akt signal transduction has 
been shown to be a crucial element in multiple cellular function, including cell 
survival, proliferation, migration and invasion induced by VEGF among other 
cytokines or growth factors [380]. This knowledge prompted us to investigate the 
PI3K/Akt signaling in the context of what influence OMSCs have on the motility of 
MSCs. The protein kinase Akt, a multifunctional regulator of cell survival, is the key 
downstream effector of PI3K. One of the major functions of Akt is to phosphorylate 
and activate mTOR, which is a protein kinase of the PI3K/Akt signaling pathway with 
a central role in the regulation of cell proliferation, survival and mobility [381]. 
Subsequently, activated mTOR regulates p70
S6K 
and PAK1
 
phosphorylation. The Akt-
mTOR-p70
S6K
-PAK1
 
cascade has been considered not only a central regulatory 
pathway of the protein translation involved in regulating cell proliferation, growth, 
differentiation and survival, but also a crucial step leading to actin cytoskeleton 
reorganization. In the present study, detailed pathway analyses revealed that the 
interaction of OMSCs with MSCs led to a rapidly increased PI3K/Akt 
phosphorylation via the activation of PDGFRs. We also observed that the downstream 
effectors of the PI3K/Akt signaling pathway, mTOR, p70
S6K
 and PAK1
 
were 
significantly activated when MSCs were stimulated with CM
OMSC
. However, the 
pharmacological suppression of the PI3K/Akt activity resulted in a complete 
attenuation of CM
OMSC
-induced cell morphology change. These results suggested that 
the PI3K/Akt kinase was activated and served as an essential downstream signaling 
molecule in OMSCs-induced MSCs migration.  
 
CONCLUSION 
In summary, we demonstrated that MSCs possess potent migratory capacity after 
stimulated by OMSCs, which can be applied in clinical setting to maximize the 
regeneration effects of the cell-based therapeutic approaches. Our results also 
indicated that the PI3K/Akt signaling pathway plays an important role in the 
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recruitment of MSCs. More intensive studies are required to identify the responsive 
host cells and to further explore the cellular and molecular mechanisms that govern 
the directional migration of the host cells, thereby allowing for optimisation of the 
therapeutic potential of pre-osteogenic differentiation of donor cells to be employed 
for bone regeneration. 
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CHAPTER 5 CONCLUSIONS AND PERSPECTIVES 
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5.1  General discussion 
Bone is a dynamic, mineralized tissue that continuously undergoes modeling and 
remodeling, and possesses the intrinsic capacity for regeneration in response to injury 
[382]. However, large bone defects resulting from trauma, tumor, and infection 
cannot heal properly without intervention, and thus the treatment for these skeletal 
deficits represents a major challenge in orthopaedic medicine. Although autologous 
bone grafting is widely used in the clinic and has been the gold standard due to its 
osteogenic, osteoinductive, and osteoconductive capacity [383], it is often associated 
with limited tissue availability, chronic pain, and considerable morbidity at the donor 
site [384, 385]. Allogenic or xenogenic bone grafting can be alternative options, but 
these strategies have certain drawbacks that include inferior osteoactivity compared to 
autologous bone grafting, donor incompatibility, and an increased risk of pathogen 
transmission [383, 386].  
 
In view of the limitations of conventional bone graft strategies, tissue engineering 
recently has emerged as a promising approach for bone repair and regeneration. The 
fundamental concept of bone tissue engineering is to combine progenitor cells, such 
as MSCs or osteogenically differentiated/mature cells (for osteogenesis) seeded onto 
biocompatible scaffolds and ideally in three-dimensional structures (for 
osteoconduction and vascular ingrowth), with appropriate growth factors (for 
osteoinduction) to trigger and utilize the endogenous biological capacity to generate 
functional bone structures.  
 
5.1.1 Scaffold materials for bone tissue engineering 
Tissue engineering scaffolds with a well-defined architecture are designed to 
influence the physical, chemical and biological environment to facilitate cell 
attachment, proliferation and differentiation. Growth factors and other biomolecules 
can be incorporated into the scaffold to guide the regulation of cellular function 
during tissue regeneration [387]. The application of the tissue engineering scaffolds 
provide the temporary support structure for tissue forming cells to synthesize desired 
tissue and to allow nutrient diffusion. Scaffolds for bone tissue engineering are 
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commonly constructed from biodegradable polymeric materials, either synthetic or 
natural [388]. However, for the regeneration of load-bearing bones, the use of 
biodegradable polymer scaffolds is challenging because of their low mechanical 
strength. Attempts have been made to reinforce the biodegradable polymers with 
biocompatible inorganic materials, such as calcium phosphate-based bioceramics and 
bioactive glass. 
 
5.1.1.1 Ceramics and bioactive glasses 
Ceramics have long been recognized as potent osteoconductive materials for bone 
tissue engineering. Calcium phosphate-based ceramics, such as hydroxyapatite (HA) 
and β-tricalcium phosphate (β-TCP) are the inorganic materials which attract most 
attention for bone repair application. When compared to β-TCP, HA shows minimal 
biodegradation, which blocks the formation of new bones and remodeling, and results 
in poor local stability or permanent stress concentration [389]. β-TCP is relatively 
balanced between bone formation and scaffold absorption. It is also a good 
biodegradable ceramic material which can supply a large quantity of calcium ion and 
sulfate ion for bone regeneration [389]. However, the mechanical strength of β-TCP is 
relatively weaker than that of HA [390, 391]. Furthermore, single β-TCP lacks of 
osteoinductivity and osteogenicity, which restricts its application in bone tissue 
engineering [389, 391]. In order to optimize the application of both HA and β-TCP, 
some researchers have manipulated different ratio of a more stable phase (HA) and a 
more soluble one (β-TCP), allowing the formation of biphasic calcium phosphate 
(BCP) with a preferable degradation rate and mechanical properties [392]. 
 
Ever since the report of the bone-bonding properties of 45S5 Bioglass
®
 more than 40 
years ago [393], bioactive glasses (BG) based on silicate [394], phosphate [395] or 
borate [396] represent another essential group of inorganic, bioactive scaffold 
materials used for bone tissue engineering. The mechanism of the bonding of BG to 
bone has been attributed to the formation of an HA-like layer on the glass surface in 
contact with the body fluid [397]. It is believed that the initial formation of HA-like 
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layer involves the adsorption of growth factors, followed by attachment, proliferation 
and differentiation of osteoprogenitor cells [390]. 45S5 Bioglass
®
 has been the gold 
standard for the application of BG in bone tissue engineering, however, as a scaffold 
material, it has several limitations. The difficulty of processing 45S5 Bioglass
® 
into 
porous 3D scaffolds results in low mechanical strength [398]. Furthermore, the low 
degradation rate of 45S5 Bioglass
® 
makes it difficult to match the rate of new bone 
tissue formation [397]. The conversion of the scaffold to an HA-like layer is often 
incomplete, thus a portion of unconverted glass remains in the scaffold, raising 
uncertainty about its effect on the local microenvironment in vivo. 
 
5.1.1.2 Synthetic degradable polymers 
Synthetic degradable polymers possess various advantages such as predictable batch 
to batch uniformity, being free from concerns of immunogenicity, and having a 
reliable source of raw material [388]. Polyglycolide (PGA), polylactide (PLA) and 
poly(lactide-co-glycolide) (PLGA) belong to the saturated aliphatic polymeric 
materials, which are one of the ancient and most frequently used groups of materials 
in the field of bone tissue engineering.  
 
PGA is a rigid, thermoplastic material with a highly crystallinity (45-55%), and 
therefore it exhibits high tensile modules with extremely low solubility in organic 
solvents [399]. Due to its excellent fiber forming ability, PGA was initially 
investigated as one of the best candidates for absorbable sutures. The first 
biodegradable synthetic suture, Dexon™, which was approved by the US Food and 
Drug Administration in the 1960s, was based on PGA. Sutures made from PGA lose 
about 50% of their strength after two weeks, 100% after four weeks and are 
completely absorbed within 4-6 months [400]. Non-woven PGA fabrics have been 
extensively used as scaffold materials for tissue regeneration due to their excellent 
degradability and good initial mechanical properties. However, the accumulation of 
the degradation product, glycolic acid, may worsen the pH environment surrounding 
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the cells and cause damage to the tissues, which may limit the biomedical application 
of PGA. 
 
PLA is synthesized by the dimerization of lactic acid. Lactic acid is a chiral molecule 
with two optical isomers, the naturally occurring L (Levorotatory) isomer, and the D 
(Dextrorotatory) isomer. Therefore, the polymers are referred to as PLLA and PDLA, 
respectively. There is also a racemic mixture of D,L-PLA named PDLLA [401]. PLLA 
is more commonly used, because the biodegradation product of PLLA is naturally 
available in the human body. PLA has linear structure, and one pendent methyl group 
which makes it more amorphous and hydrophobic than PGA [388]. However, being 
more hydrophobic, the degradation rate of PLA is relatively low. It has been reported 
that high molecular weight PLLA can take more than five years to be completely 
absorbed, whereas about one year is needed for PDLLA [402]. Being a low strength 
polymer with faster degradation rate compared to PLLA, PDLLA is the preferred 
candidate for developing drug delivery vehicles and as low strength scaffold material 
for tissue regeneration.  
 
PLGA is synthesized through co-polymerizing lactide and glycolide, the mechanical 
and biodegradation properties of which are based on the ratio of individual monomers 
in the composite. Co-polymers of 25-75% L-LA with glycolide are amorphous due to 
the disruption of the regularity of the polymer chain. PLGA polymers containing 
50:50 ratio of lactide and glycolide show much greater degradation rate than those 
containing higher proportion of either of the two monomers [403]. PLGA 
demonstrates good cell adhesion and proliferation, making it a favorable candidate for 
tissue engineering applications, especially in blood vessel, bone and cartilage 
regeneration [404-406]. A major concern about the application of the synthetic 
polymers is the chemicals (additives, traces of catalysts and inhibitors) and monomers 
(lactic acid and glycolic acid) released from the degradation of polymer, resulting in 
local and systemic host reactions that may cause clinical complications [407]. One of 
the by-products, lactic acid, is reported to potentially create an adverse cellular 
response at the implant site by reducing the local pH, leading to the release of 
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prostaglandin E2 (PGE2), a bone resorbing and inflammatory mediator, by human 
synovial fibroblasts and murine macrophages [408]. The toxic residues resulting from 
the chemical cross-linking also make these synthetic polymers less desirable for 
implantable devices [409, 410]. 
 
5.1.1.3 Natural degradable polymers 
Natural polymers can be considered as the first biodegradable scaffold biomaterials 
used clinically. Most of the naturally occurring polymers undergo enzymatic 
degradation, and their degradation rate varies significantly with the site of 
implantation, depending on the availability and concentration of the enzymes. The 
most commonly investigated natural scaffold materials include alginate, collagen, 
hyaluronic acid, fibrin, silk and chitosan. Much of the interest in these natural 
polymers stems from their superior biocompatibility, relative abundance, the ability to 
present receptor-binding ligands to cells, the susceptibility to cell-triggered proteolytic 
degradation, and the possibility to mimic the innate microenvironment for bone tissue 
regeneration. 
 
Collagen is the most abundant protein in mammals, constituting up to one-third of 
total body protein [411]. The individual polypeptide chains of collagen contain 20 
different amino acids and the precise composition varies among different tissues [412]. 
Variations in the amino acid sequence give rise to the different types of collagen, 
among which type I collagen is the most predominant type found in the extracellular 
matrix (ECM), especially in tissues such as tendon, periosteum and bone [413]. 
Collagen has been among the most widely used biomaterials for bone tissue 
engineering due to its abundance, biocompatibility, high porosity, low antigenicity 
and absorbability in the body [414, 415].  
 
The main disadvantage of collagen is its poor mechanical strength, especially 
compared with native bone. To enhance its mechanical property, collagen is cross-
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linked by a variety of chemical agents or physical treatments. However, the 
commonly used chemical agents such as glutaraldehyde and polyepoxy are cytotoxic 
at certain concentrations, thus their use has been limited due to the residual cross-
linking compounds remaining in the collagen scaffold [416]. On the other hand, 
overexposure to physical treatments, such as dehydrothermal treatment, ultraviolet 
irradiation, gamma irradiation and microwave irradiation may lead to collagen 
degradation [415]. Another major concern about the application of allogenic or 
xenogenic collagen is its potential antigenicity and immunogenicity [417]. However, 
reports have shown that the adverse immunological responses only occur in rare cases 
and generally settle within a few months, especially in the application of type I 
collagen [417, 418]. Premature absorption and other adverse effects of collagen 
implantation have been rare and the combined use with immunosuppressant has been 
shown to be effective [419]. 
 
5.1.2 Growth factors delivery 
With improved understanding of fracture healing and bone regeneration at the 
molecular level [135], recent research has demonstrated that the incorporation or 
release of growth factors, such as basic fibroblast growth factor (bFGF), bone 
morphogenetic proteins (BMPs), insulin-like growth factor (IGF), platelet-derived 
growth factor (PDGF), transforming growth factor β (TGF-β), and vascular 
endothelial growth factor (VEGF) can improve the biological performance of 
scaffolds as cell carriers. Of these molecules, BMPs are the most extensively studied, 
as they are potent osteoinductive factors. More than 30 BMPs have been identified so 
far. Of the known BMPs, BMP-2, -4, and -7 are each individually able to induce new 
bone formation at ectopic and orthotopic sites [78, 420-424]. However, the clinical 
use of BMPs has been limited because of the expensive and difficult purification 
process. Furthermore, the proteins isolated from allogenic or xenogenic sources may 
carry potential health risks. The application of recombinant human BMP (rhBMP) has 
been reported in a number of animal models as well as a few human clinical trials 
[425-427]. The therapeutic potential of rhBMPs-2, -4, and -7 has been proven in 
selected fracture repair and bone regeneration process. However, the safety issues 
110 | P a g e  
 
risen from the supraphysiological concentrations of growth factors needed to obtain 
the desired osteoinductive effects, the high cost of treatment, and more importantly, 
the possibility of local inflammation and edema [428], ectopic bone formation [429] 
and carcinogenicity [430] may have reduced the clinical research enthusiasm. 
 
Unlike bone graft transplants where there is a pre-existing vascular supply, synthetic 
bone constructs are devoid of vasculature. Researchers have been trying to address 
this issue of whether it is a pre-vascularised scaffold developed in vitro or the release 
of angiogenic factors from scaffold that promote angiogenesis in situ that will 
enhance optimal bone regeneration. VEGF has been one of the most used growth 
factors in the application of bone tissue engineering, because it is the key regulator in 
a cascade of molecular and cellular events that ultimately lead to the development of 
the vascular system [365]. Even though supplying VEGF alone was not sufficient to 
initiate the cascade of bone regeneration in the critical-sized calvarial defects, it has 
been reported that the combination of angiogenic and osteogenic factors can stimulate 
bone healing [431]. Dual release of VEGF and BMP-2 from biodegradable scaffolds 
seeded with BMSCs has been demonstrated to be effective for bone repair and 
regeneration in a murine femur bone defect model [432]. PLGA scaffolds containing 
plasmids encoding DNA for BMP-4 and VEGF have also shown greater bone forming 
ability when implanted subcutaneously [433]. Hence, the combined delivery system 
of growth factors at different rate kinetics locally from biodegradable scaffolds may 
be a promising approach to enhance the reparative mechanism of bone defects. 
Although these findings are interesting, the possible application of VEGF in bone 
tissue engineering is limited by the short biological half-life, the need for repeated 
examinations for optimum dosage, and the expensive cost for the provision of a 
sustained concentration at the site of bone regeneration. 
 
5.1.3 Cell sources 
Recent advances in stem cell biology and regenerative medicine enable the 
development of cell-based therapy. Cell-based bone tissue engineering approaches 
entail the seeding of a scaffold with progenitor cells or mature cells that will be 
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delivered to and retained within the lesion site. It has been reported that stem cell 
delivery is likely to produce more reliable and effective results in the management of 
bone defect compared to the traditional treatments [434, 435]. MSCs can be easily 
isolated from readily accessible bone marrow among other tissues. Additionally, in 
vitro expansion potential enables the generation of a sufficient number of bone 
marrow-derived MSCs for transplantation [436]. Immunosuppressive and anti-
inflammatory functions [437, 438], homing ability to injured sites [439, 440] and 
capability to modify the microenvironment by paracrine factors [441] enable MSCs to 
become a promising candidate for cell-based bone tissue engineering. 
 
It has been noted that stem cells alone are not sufficient for a long lasting regenerative 
effect. The acceleration of endogenous regenerative mechanism that involves host cell 
recruitment, a biological process also known as cell homing, has been considered as a 
highly useful and practical approach for bone tissue regeneration [151, 310]. 
Although there are reports claiming that the MSCs from systemic sources which 
express CXCR4 at their surface actively participate in bone regeneration [442, 443], it 
is generally accepted that the skeletal progenitors within the local environment play a 
more predominant role [444]. These skeletal progenitors may come from the bone 
marrow within the injured bone, from the surrounding periosteum, and from soft 
tissues in close proximity with the bone. However, all these tissues are closely linked, 
which makes it difficult to distinguish their participation during bone repair and 
regeneration.  
 
There is a significant body of evidence that demonstrates the transplanted cells can 
either differentiate into bone forming cells or attract other cell types to build up bone 
tissue and simultaneously resorb cell carrier or bone substitute material [445-447]. 
Thus, the development of donor cell delivery approaches which can establish key 
interactions with host cells in ways that unlock the endogenous power for robust 
regeneration becomes increasingly important. The systemic delivery of donor cells 
does not require invasive surgical intervention, and the donor cells could potentially 
be injected at multiple time points. Furthermore, systemic delivery may be more 
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beneficial to certain bone disorders affecting the whole body [448, 449]. However, 
when delivered systemically, the donor cells contribute modestly to bone forming 
cells [444]. Therefore, systemic delivery may not be ideal to direct exogenous cells 
toward osteogenesis in a bone defect site. To augment the therapeutic effects of donor 
cells, a number of strategies have been developed to deliver donor cells locally and 
support bone regeneration. It has been reported that the volume of mineralized callus 
is related with the number and concentration of fibroblast colony-forming units in the 
bone marrow graft [450], indicating that the number of donor cells may play a part in 
the osteogenic stimulation. Osteogenic differentiation of donor cells prior to 
implantation may favor superior bone regeneration [19, 451, 452], but it decreases the 
expansion capacity. Many efforts are also focused on the design of scaffolds to create 
a biocompatible environment and provide proper vascularization. Scaffolds loaded 
with angiogenic growth factors have been employed initially [453, 454]. Currently, 
the implantation of composites of MSCs mixed with endothelial progenitor cells 
(EPCs) is considered as a promising alternative [455]. 
 
5.1.4 Animal models for bone repair investigations 
It is generally accepted that an ideal animal model for bone repair and regeneration 
should mimic clinical conditions of bone injury, be able to utilize fixation, allow 
mechanical load, create a permissive microenvironment for diffusion of nutrients and 
growth factors, and permit angiogenesis [456]. The model of ectopic bone formation 
is commonly employed because it is the least invasive and more suitable for 
preliminary screening of donor cells, scaffolds and growth factors [457]. Nearly any 
mammal can be chosen, from mouse and rat to rabbit, dog, and pig among numerous 
others. To date, the rodent model is the most popular and widely used due to the low 
cost, lax skin and availability of immunodeficient animals. A wide variety of locations 
have been used for ectopic bone formation model, including subcutaneous, 
intramuscular, and kidney capsule transplantation [458]. Subcutaneous implantation is 
the simplest of all experimental models of ectopic bone formation. However, the 
subcutaneous model is largely devoid of appropriate mechanical stimulation, which 
may lead to eventual degradation of the newly formed bone. The physical 
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identification of the implant can be challenging, especially when the newly formed 
bone shares similar color with the surrounding dermal tissues. The bone forming 
capacity is actually inferior in subcutaneous models compared to other ectopic models 
due to reduced vascularization and blood flow. The lax skin may also allow 
potentially significant migration of the implants, making it difficult for sample 
collection.  
 
For non-weight bearing testing, the bone defect can be created within the calvaria, rib 
or mandibles, which have comparatively low mechanical forces. In this model, most 
scaffold materials can be designed to fit the size of the defect and do not require 
further fixation. For weight bearing testing, the defect can be made in long bones, 
such as femur or tibia, using an osteotomy approach or a traumatic approach [456]. 
Osteotomy can surgically remove the required length of bone from a predetermined 
site, producing a consistent defect in all subjects. However, this does not reflect the 
actual clinical conditions following traumatic injury which produce a jagged cut edge 
and traumatize both the bone and surrounding soft tissue. The disadvantage of the 
traumatic approach is the potential for larger variation in defect size among subjects. 
In a weight bearing site, the bone defect is reconstructed with the test material alone 
or in combination with cells and growth factors and fixed using external or internal 
fixation. Since the animal will start to move after recovery, the biomechanical 
properties of the selected scaffold are crucial for optimum bone regeneration in a 
weight bearing bone defect. Scaffolds need to be strong enough to allow weight-
bearing during the initial stage of the regenerative process but also biodegradable at 
the right time to allow bone remodeling [457]. The contribution of host and donor 
cells to bone formation in these complex animal models still remains to be elucidated. 
 
5.2  Project summary 
At the time when this project was first conceived, very few attempts had been made to 
understand the relationship between host cells and donor cells, although an apparent 
correlation between these two counterparts is present at a clinical scale [130-132]. 
The project sought to advance the knowledge and understanding of the interactions 
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between donor cells and host cells during osteogenesis, the involvement of host cells 
in the bone healing process, and the role of pre-programmed donor cells in the 
recruitment of host cells. The ultimate goal is to unveil the potential molecular 
mechanisms involved during this process at a cellular level. This project was designed 
with three separate but closely–linked segments, which in the end led to three 
independent reports summarized as follows. 
 
Firstly, in REPORT ONE, we highlighted the concept of cell-based therapy and the 
discrepancies that exist in the literature with respect to the interaction and 
involvement of host cells and donor cells during osteogenesis. Having demonstrated 
the enhanced migration tendency of MSCs towards OMSCs in the in vitro migration 
assay, we then further investigated the role of donor cells during osteogenesis in a 
small animal model. Using type-I collagen as a cell-carrier, donor cells were 
implanted subcutaneously or into skull defects. Pre-manipulation of the donor cells 
was found to significantly enhance mineralization and bone formation. The most 
interesting finding was that in both ectopic and orthotopic sites, the implantation of 
OMSCs could attract host cells and initiate osteogenesis. These findings provide some 
insight into the paracrine effect of the secreted factors from OMSCs on the host cell 
recruitment in vivo. 
 
Using a combined in situ hybridisation and immunohistochemical staining technique, 
our histological images revealed that the donor OMSCs strongly expressed VEGF, 
giving a clue that VEGF secreted by donor OMSCs may play a role in the host cell 
recruitment. Therefore, in REPORT TWO we particularly focused on the potential 
effect of VEGF. Our data showed that VEGF secretion increased dramatically in 
MSCs after osteogenic differentiation in vitro. The secretion of VEGF promoted the 
motility of MSCs with elongated actin filament and enhanced the expression of 
CXCL12/CXCR4, which is believed to be the most important axis that contributes to 
MSCs homing to areas of damaged tissue. In vivo findings revealed that blocking 
VEGF with neutralizing antibody led to a remarkable decrease of MSC recruitment 
and new bone formation. Thus, the results from this study for the first time showed 
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that VEGF secreted by transplanted OMSCs altered the cell morphology and 
CXCL12/CXCR4 expression pattern of MSCs, triggering the downstream signaling 
pathway, which may explain the host cell recruitment phenomenon observed in our 
previous study. 
 
In REPORT THREE, we first demonstrated that MSCs express limited functional 
VEGFRs, which is in agreement with other reports [200, 372, 379]. As VEGF and 
PDGF are closely related members from the VEGF/PDGF super family, VEGFRs and 
PDGFRs are also structurally related, so we speculated that VEGF may exert its 
paracrine effect through the activation of PDGFRs. Therefore, we furthered our study 
and the results showed that the function of VEGFRs had no impact on MSC 
directional migration, instead, the functional cell surface PDGFRs were crucial 
determinants in mediating MSC migration induced by OMSCs. In order to unveil the 
root causes of the enhanced host cell recruitment, our study probed cell signaling 
pathways that are highly related to cell polarization and migration, such as PI3K/Akt 
and Erk1/2. Our data showed that OMSCs induced a swift activation of PI3K/Akt in 
MSCs, leading to the phosphorylation of downstream effectors, such as mTOR, 
p70
S6K
, and PAK1. This segment of study showed that the VEGF secreted from 
OMSCs promoted MSCs directional migration via the activation of PDGFRs, which 
then led to the activation of the PI3K/Akt signaling pathway.  
 
5.3  Future direction 
In this thesis, we mainly focused on the paracrine effect of VEGF secreted from 
OMSCs, however, there are other cytokines derived from OMSCs which may also 
play a significant role in host cell recruitment. Therefore, further studies are justified 
to identify such soluble factors, probably by using proteomic mapping of the 
conditioned medium derived from OMSCs. Also, during the last decade, growing 
evidence has indicated that preferential activation of PI3K/Akt at the side of the cell 
facing the chemoattractant gradient is critical for establishing a new leading edge, cell 
polarization, and directional movement in a wide range of motile cell types [240, 459, 
460]. Thus the clear recognition that the PI3K/Akt signaling pathway underlines the 
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recruitment of host cells towards bone defect sites makes the clarification of 
downstream targets of central importance to our understanding of bone defect healing. 
More advanced animal models, such as knock-ins encoding catalytically inactive Akt 
mutants, will likely provide a more accurate picture of the role of the PI3K/Akt 
signaling pathway in bone tissue regeneration driven by the recruited endogenous 
cells. It will also be important to further define the role of crosstalk between distinct 
downstream branches of the PI3K/Akt signaling pathway, as well as the networking 
with other signaling pathways, in the ultimate outcome of optimal bone remodelling 
and regeneration. 
 
Taken together, the observations from this work suggest that host cells and donor cells 
interact closely in the bone healing process after cell transplantation. We have 
reported for the first time that the implanted OMSCs play an integral role in recruiting 
host cells towards the implantation sites, and more importantly, we have demonstrated 
the factors secreted from donor cells (e.g. VEGF) can induce cell morphology 
changes and enhance expression of CXCL12/CXCR4. We also reported that VEGF 
secreted by OMSCs can signal through PDGFRs in MSCs. The signal is then 
amplified by the activation of the PI3K/Akt kinase, ultimately leading to endogenous 
cell recruitment and robust bone regeneration. This highlights the novelty of the 
obtained results and therefore provides the scientific rationale to define new 
therapeutic approaches for bone defect healing. 
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